UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q


☑			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
for the quarterly period ended ~~June~~September 30, 2020
OR
☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

COMMISSION FILE NUMBER: 001-37590

CERECOR INC.

(Exact name of registrant as specified in its charter)


Delaware (State of incorporation)			45-0705648 (I.R.S. Employer Identification No.)
540 Gaither Road, Suite 400 Rockville, Maryland 20850 (Address of principal executive offices)			(410) 522-8707 (Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.001 par value	CERC	Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b‑2 of the Exchange Act.


Large accelerated filer ☐						Accelerated filer ☑
Non-accelerated filer ☐						Smaller reporting company ☑
Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☑

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes ☐ No ☑

As of ~~August 4,~~November 5, 2020, the registrant had ~~74,900,047~~74,910,047 shares of common stock outstanding.

Table of Contents

CERECOR INC.

FORM 10-Q

For the Quarter Ended ~~June~~September 30, 2020

TABLE OF CONTENTS

Page

PART I.

FINANCIAL INFORMATION

Item 1.

Financial Statements

Condensed Consolidated Balance Sheets as of ~~June~~September 30, 2020 (Unaudited) and December 31, 2019

Condensed Consolidated Statements of Operations (Unaudited) for the Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2020 and 2019

Condensed Consolidated Statements of Cash Flows (Unaudited) for the ~~Six~~Nine Months Ended ~~June~~September 30, 2020 and 2019

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) for the Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2020 and 2019

Notes to Unaudited Condensed Consolidated Financial Statements

1110

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

3330

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

4542

Item 4.

Controls and Procedures

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

CERECOR INC. and SUBSIDIARIES

Condensed Consolidated Balance Sheets


		June 30, 2020		December 31, 2019			September 30, 2020		December 31, 2019
		(unaudited)					(unaudited)
Assets	Assets					Assets
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	45,390,553	$	3,609,438	Cash and cash equivalents	$	33,391,427	$	3,609,438
Accounts receivable, net	Accounts receivable, net	2,031,682		1,001,645		Accounts receivable, net	1,671,121		1,001,645
Other receivables	Other receivables	1,953,036		4,240,572		Other receivables	4,285,393		4,240,572
Inventory, net	Inventory, net	12,196		21,334		Inventory, net	9,060		21,334
Prepaid expenses and other current assets	Prepaid expenses and other current assets	823,900		706,968		Prepaid expenses and other current assets	1,544,101		706,968
Restricted cash, current portion	Restricted cash, current portion	33,449		17,535		Restricted cash, current portion	131,844		17,535
Investment in Aytu	Investment in Aytu	—		7,628,947		Investment in Aytu	0		7,628,947
Current assets of discontinued operations	Current assets of discontinued operations	—		497,577		Current assets of discontinued operations	0		497,577
Total current assets	Total current assets	50,244,816		17,724,016		Total current assets	41,032,946		17,724,016
Property and equipment, net	Property and equipment, net	1,740,610		1,447,663		Property and equipment, net	1,707,806		1,447,663
Intangible assets, net	Intangible assets, net	2,292,175		2,426,258		Intangible assets, net	1,888,675		2,426,258
Goodwill	Goodwill	14,409,088		14,409,088		Goodwill	14,409,088		14,409,088
Restricted cash, net of current portion	Restricted cash, net of current portion	180,336		101,945		Restricted cash, net of current portion	148,642		101,945
Deferred tax asset, net		337,797		—
Total assets	Total assets	$	69,204,822	$	36,108,970	Total assets	$	59,187,157	$	36,108,970
Liabilities and stockholders’ equity	Liabilities and stockholders’ equity					Liabilities and stockholders’ equity
Current liabilities:	Current liabilities:					Current liabilities:
Accounts payable	Accounts payable	$	2,557,702	$	2,077,524	Accounts payable	$	1,926,989	$	2,077,524
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities	6,487,658		5,640,252		Accrued expenses and other current liabilities	8,810,722		5,640,252
Income taxes payable	Income taxes payable	—		551,671		Income taxes payable	0		551,671
Current liabilities of discontinued operations	Current liabilities of discontinued operations	5,549,751		3,891,012		Current liabilities of discontinued operations	5,833,729		3,891,012
Total current liabilities	Total current liabilities	14,595,111		12,160,459		Total current liabilities	16,571,440		12,160,459
Royalty obligation	Royalty obligation	2,000,000		—		Royalty obligation	2,000,000		0
Deferred tax liability, net	Deferred tax liability, net	—		85,981		Deferred tax liability, net	114,981		85,981
Other long-term liabilities	Other long-term liabilities	2,031,560		1,111,965		Other long-term liabilities	1,933,699		1,111,965
Long-term liabilities of discontinued operations	Long-term liabilities of discontinued operations	—		1,755,000		Long-term liabilities of discontinued operations	0		1,755,000
Total liabilities	Total liabilities	18,626,671		15,113,405		Total liabilities	20,620,120		15,113,405
Stockholders’ equity:	Stockholders’ equity:					Stockholders’ equity:
Common stock—$0.001 par value; 200,000,000 shares authorized at June 30, 2020 and December 31, 2019; 74,900,047 and 44,384,222 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively		74,899		44,384
Preferred stock—$0.001 par value; 5,000,000 shares authorized at June 30, 2020 and December 31, 2019; 1,257,143 and 2,857,143 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively		1,257		2,857
Common stock—$0.001 par value; 200,000,000 shares authorized at September 30, 2020 and December 31, 2019; 74,900,047 and 44,384,222 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively						Common stock—$0.001 par value; 200,000,000 shares authorized at September 30, 2020 and December 31, 2019; 74,900,047 and 44,384,222 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	74,899		44,384
Preferred stock—$0.001 par value; 5,000,000 shares authorized at September 30, 2020 and December 31, 2019; 1,257,143 and 2,857,143 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively						Preferred stock—$0.001 par value; 5,000,000 shares authorized at September 30, 2020 and December 31, 2019; 1,257,143 and 2,857,143 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	1,257		2,857
Additional paid-in capital	Additional paid-in capital	199,191,022		135,238,941		Additional paid-in capital	200,638,553		135,238,941
Accumulated deficit	Accumulated deficit	(148,689,027)		(114,290,617)		Accumulated deficit	(162,147,672)		(114,290,617)
Total stockholders’ equity	Total stockholders’ equity	50,578,151		20,995,565		Total stockholders’ equity	38,567,037		20,995,565
Total liabilities and stockholders’ equity	Total liabilities and stockholders’ equity	$	69,204,822	$	36,108,970	Total liabilities and stockholders’ equity	$	59,187,157	$	36,108,970

See accompanying notes to the unaudited condensed consolidated financial statements.

Table of Contents

CERECOR INC. and SUBSIDIARIES

Condensed Consolidated Statements of Operations (Unaudited)


		Three Months Ended						Six Months Ended							Three Months Ended				Nine Months Ended
		June 30,						June 30,							September 30,				September 30,
		2020		2019		2020		2019			2020		2019		2020		2019
Revenues:	Revenues:									Revenues:
Product revenue, net	Product revenue, net	$	1,337,764	$	1,391,942	$	4,091,628	$	3,968,310	Product revenue, net	$	1,110,794	$	2,101,232	$	5,202,423	$	6,069,543
License and other revenue										License and other revenue	0		100,000		0		100,000
Total revenues, net	Total revenues, net	1,337,764		1,391,942		4,091,628		3,968,310		Total revenues, net	1,110,794		2,201,232		5,202,423		6,169,543

Operating expenses:	Operating expenses:									Operating expenses:
Cost of product sales	Cost of product sales	77,580		(1,496,677)		144,139		(744,128)		Cost of product sales	76,636		132,382		220,775		(611,747)
Research and development	Research and development	5,916,869		3,712,596		10,684,619		7,113,785		Research and development	8,871,574		1,743,435		19,556,194		8,857,220
Acquired in-process research and development	Acquired in-process research and development	—		—		25,549,344		—		Acquired in-process research and development	0		0		25,549,344		0
General and administrative	General and administrative	6,101,475		2,340,634		8,777,088		5,016,243		General and administrative	4,573,292		2,638,023		13,350,380		7,654,266
Sales and marketing	Sales and marketing	653,265		325,861		1,329,790		722,137		Sales and marketing	462,318		214,207		1,792,108		936,343
Amortization expense	Amortization expense	403,500		334,747		834,083		669,495		Amortization expense	403,500		334,748		1,237,583		1,004,243
Change in fair value of contingent consideration	Change in fair value of contingent consideration	—		(1,277,150)		—		(1,256,210)		Change in fair value of contingent consideration	0		0		0		(1,256,210)
Total operating expenses	Total operating expenses	13,152,689		3,940,011		47,319,063		11,521,322		Total operating expenses	14,387,320		5,062,795		61,706,384		16,584,115
Loss from continuing operations	Loss from continuing operations	(11,814,925)		(2,548,069)		(43,227,435)		(7,553,012)		Loss from continuing operations	(13,276,526)		(2,861,563)		(56,503,961)		(10,414,572)
Other income (expense):
Other income:										Other income:
Change in fair value of Investment in Aytu	Change in fair value of Investment in Aytu	(1,872,031)		—		5,207,789		—		Change in fair value of Investment in Aytu	0		0		5,207,789		0
Change in fair value of warrant liability and unit purchase option liability		2,647		18,910		13,928		(28,668)
Other income (expense), net		395,800		—		395,800		(9,400)
Interest income, net		8,711		38,412		18,501		68,632
Total other (expense) income, net from continuing operations		(1,464,873)		57,322		5,636,018		30,564
Other income, net										Other income, net	18,668		52,711		446,897		83,273
Total other income, net from continuing operations										Total other income, net from continuing operations	18,668		52,711		5,654,686		83,273
Loss from continuing operations before taxes	Loss from continuing operations before taxes	(13,279,798)		(2,490,747)		(37,591,417)		(7,522,448)		Loss from continuing operations before taxes	(13,257,858)		(2,808,852)		(50,849,275)		(10,331,299)
Income tax (benefit) expense		(453,957)		53,446		(2,610,812)		184,119
Income tax expense (benefit)										Income tax expense (benefit)	3,282		121,640		(2,607,530)		305,759
Loss from continuing operations	Loss from continuing operations	$	(12,825,841)	$	(2,544,193)	$	(34,980,605)	$	(7,706,567)	Loss from continuing operations	$	(13,261,140)	$	(2,930,492)	$	(48,241,745)	$	(10,637,058)
(Loss) income from discontinued operations, net of tax	(Loss) income from discontinued operations, net of tax	(455,463)		(3,678,906)		582,195		(5,970,580)		(Loss) income from discontinued operations, net of tax	(197,505)		(1,085,962)		384,690		(7,056,543)
Net loss	Net loss	$	(13,281,304)	$	(6,223,099)	$	(34,398,410)	$	(13,677,147)	Net loss	$	(13,458,645)	$	(4,016,454)	$	(47,857,055)	$	(17,693,601)

Net (loss) income per share of common stock, basic and diluted:	Net (loss) income per share of common stock, basic and diluted:									Net (loss) income per share of common stock, basic and diluted:
Continuing operations	Continuing operations	$	(0.18)	$	(0.05)	$	(0.53)	$	(0.14)	Continuing operations	$	(0.16)	$	(0.05)	$	(0.68)	$	(0.19)
Discontinued operations	Discontinued operations	(0.01)		(0.06)		0.01		(0.10)		Discontinued operations	(0.01)		(0.02)		0.00		(0.12)
Net loss per share of common stock, basic and diluted	Net loss per share of common stock, basic and diluted	$	(0.19)	$	(0.11)	$	(0.52)	$	(0.24)	Net loss per share of common stock, basic and diluted	$	(0.17)	$	(0.07)	$	(0.68)	$	(0.31)

Net (loss) income per share of preferred stock, basic and diluted:	Net (loss) income per share of preferred stock, basic and diluted:									Net (loss) income per share of preferred stock, basic and diluted:
Continuing operations	Continuing operations	$	(0.93)	$	(0.23)	$	(2.66)	$	(0.68)	Continuing operations	$	(0.82)	$	(0.26)	$	(3.40)	$	(0.94)
Discontinued operations	Discontinued operations	(0.03)		(0.32)		0.04		(0.53)		Discontinued operations	(0.01)		(0.09)		0.02		(0.62)
Net loss per share of preferred stock, basic and diluted	Net loss per share of preferred stock, basic and diluted	$	(0.96)	$	(0.55)	$	(2.62)	$	(1.21)	Net loss per share of preferred stock, basic and diluted	$	(0.83)	$	(0.35)	$	(3.38)	$	(1.56)

See accompanying notes to the unaudited condensed consolidated financial statements.

Table of Contents

CERECOR INC. and SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited)

Table of Contents


		Six Months Ended June 30,							Nine Months Ended September 30,
		2020		2019			2020		2019
Operating activities	Operating activities					Operating activities
Net loss	Net loss	$	(34,398,410)	$	(13,677,147)	Net loss	$	(47,857,055)	$	(17,693,601)
Adjustments to reconcile net loss used in operating activities:	Adjustments to reconcile net loss used in operating activities:					Adjustments to reconcile net loss used in operating activities:
Depreciation and amortization	Depreciation and amortization	878,949		2,203,423		Depreciation and amortization	1,304,882		3,266,313
Impairment of intangible assets	Impairment of intangible assets	—		1,449,121		Impairment of intangible assets	0		1,449,121
Stock-based compensation	Stock-based compensation	3,901,897		1,123,402		Stock-based compensation	5,349,428		1,942,196
Acquired in-process research and development	Acquired in-process research and development	25,549,344		—		Acquired in-process research and development	25,549,344		0
Deferred taxes	Deferred taxes	(423,778)		18,870		Deferred taxes	29,000		28,823
Amortization of inventory fair value associated with acquisition of TRx and Avadel's pediatric products	Amortization of inventory fair value associated with acquisition of TRx and Avadel's pediatric products	—		40,240		Amortization of inventory fair value associated with acquisition of TRx and Avadel's pediatric products	0		107,272
Change in fair value of Investment in Aytu	Change in fair value of Investment in Aytu	(5,207,789)		—		Change in fair value of Investment in Aytu	(5,207,789)		0
Change in fair value of warrant liability and unit purchase option liability	Change in fair value of warrant liability and unit purchase option liability	(13,928)		28,668		Change in fair value of warrant liability and unit purchase option liability	(14,054)		(6,823)
Change in value of Guarantee	Change in value of Guarantee	(1,755,000)		—		Change in value of Guarantee	(1,755,000)		0
Change in fair value of contingent consideration	Change in fair value of contingent consideration	—		(811,948)		Change in fair value of contingent consideration	0		(1,009,168)
Changes in assets and liabilities:	Changes in assets and liabilities:					Changes in assets and liabilities:
Accounts receivable, net	Accounts receivable, net	(532,460)		297,267		Accounts receivable, net	(171,899)		(1,798,216)
Other receivables	Other receivables	(1,851,867)		5,326,000		Other receivables	(4,184,225)		5,260,807
Inventory, net	Inventory, net	9,138		452,931		Inventory, net	12,274		601,241
Prepaid expenses and other assets	Prepaid expenses and other assets	(23,782)		664,454		Prepaid expenses and other assets	(743,983)		(140,503)
Accounts payable	Accounts payable	82,674		(666)		Accounts payable	(548,039)		(619,669)
Income taxes payable	Income taxes payable	288,329		(639,784)		Income taxes payable	288,329		(1,017,804)
Accrued expenses and other liabilities	Accrued expenses and other liabilities	(815,014)		(6,313,686)		Accrued expenses and other liabilities	1,775,039		(6,573,918)
License obligations						License obligations	0		(1,250,000)
Lease liability, net	Lease liability, net	17,510		—		Lease liability, net	9,794		0
Net cash used in operating activities	Net cash used in operating activities	(14,294,187)		(9,838,855)		Net cash used in operating activities	(26,163,954)		(17,453,929)
Investing activities	Investing activities					Investing activities
Proceeds from sale of Investment in Aytu, net	Proceeds from sale of Investment in Aytu, net	12,836,736		—		Proceeds from sale of Investment in Aytu, net	12,836,736		0
Net cash paid in merger with Aevi	Net cash paid in merger with Aevi	(1,250,650)		—		Net cash paid in merger with Aevi	(1,250,650)		0
Purchase of property and equipment	Purchase of property and equipment	—		(256,926)		Purchase of property and equipment	(62,658)		(262,011)
Net cash provided by (used in) investing activities	Net cash provided by (used in) investing activities	11,586,086		(256,926)		Net cash provided by (used in) investing activities	11,523,428		(262,011)
Financing activities	Financing activities					Financing activities
Proceeds from underwritten public offering, net	Proceeds from underwritten public offering, net	35,427,963		8,975,960		Proceeds from underwritten public offering, net	35,427,963		8,975,960
Proceeds from registered direct offering, net	Proceeds from registered direct offering, net	5,136,184		—		Proceeds from registered direct offering, net	5,136,184		0
Proceeds from sale of shares pursuant to common stock private placement, net	Proceeds from sale of shares pursuant to common stock private placement, net	3,887,991		—		Proceeds from sale of shares pursuant to common stock private placement, net	3,887,991		3,737,400
Proceeds from exercise of stock options and warrants	Proceeds from exercise of stock options and warrants	92,342		256,816		Proceeds from exercise of stock options and warrants	92,342		257,993
Proceeds from shares purchased through employee stock purchase plan	Proceeds from shares purchased through employee stock purchase plan	132,910		127,537		Proceeds from shares purchased through employee stock purchase plan	132,910		127,537
Restricted Stock Units withheld for taxes	Restricted Stock Units withheld for taxes	(93,869)		(18,057)		Restricted Stock Units withheld for taxes	(93,869)		(33,959)
Payment of contingent consideration	Payment of contingent consideration	—		(379,255)		Payment of contingent consideration	0		(567,911)
Payment of long-term debt	Payment of long-term debt	—		(48,684)		Payment of long-term debt	0		(73,026)
Net cash provided by financing activities	Net cash provided by financing activities	44,583,521		8,914,317		Net cash provided by financing activities	44,583,521		12,423,994
Increase (decrease) in cash, cash equivalents and restricted cash	Increase (decrease) in cash, cash equivalents and restricted cash	41,875,420		(1,181,464)		Increase (decrease) in cash, cash equivalents and restricted cash	29,942,995		(5,291,946)
Cash, cash equivalents, and restricted cash at beginning of period	Cash, cash equivalents, and restricted cash at beginning of period	3,728,918		10,746,756		Cash, cash equivalents, and restricted cash at beginning of period	3,728,918		10,746,756
Cash, cash equivalents, and restricted cash at end of period	Cash, cash equivalents, and restricted cash at end of period	$	45,604,338	$	9,565,292	Cash, cash equivalents, and restricted cash at end of period	$	33,671,913	$	5,454,810
Supplemental disclosures of cash flow information	Supplemental disclosures of cash flow information					Supplemental disclosures of cash flow information
Cash paid for interest	Cash paid for interest	$	—	$	525,000	Cash paid for interest	$	0	$	787,500
Cash paid for taxes	Cash paid for taxes	$	316,000	$	852,025	Cash paid for taxes	$	316,000	$	1,326,025
Supplemental disclosures of non-cash activities	Supplemental disclosures of non-cash activities					Supplemental disclosures of non-cash activities
Issuance of common stock in Aevi Merger	Issuance of common stock in Aevi Merger	$	15,495,578	$	—	Issuance of common stock in Aevi Merger	$	15,495,578	$	0
Leased asset obtained in exchange for new operating lease liability	Leased asset obtained in exchange for new operating lease liability	$	376,448	$	743,025	Leased asset obtained in exchange for new operating lease liability	$	376,448	$	743,025

Table of Contents

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:

~~Table of Contents~~


		June 30,							September 30,
		2020		2019			2020		2019

Cash and cash equivalents	Cash and cash equivalents	$	45,390,553	$	9,386,865	Cash and cash equivalents	$	33,391,427	$	5,250,651
Restricted cash, current	Restricted cash, current	33,449		26,265		Restricted cash, current	131,844		102,214
Restricted cash, non-current	Restricted cash, non-current	180,336		152,162		Restricted cash, non-current	148,642		101,945
Total cash, cash equivalents and restricted cash	Total cash, cash equivalents and restricted cash	$	45,604,338	$	9,565,292	Total cash, cash equivalents and restricted cash	$	33,671,913	$	5,454,810

See accompanying notes to the unaudited condensed consolidated financial statements.

Table of Contents

CERECOR INC. and SUBSIDIARIES

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited)

Common stock Preferred Stock Additional paid-in Accumulated Total stockholders’
Shares Amount Shares Amount capital deficit equity
Three Months Ended June 30, 2020
Balance, March 31, 2020 59,560,252 $ 59,560 1,257,143 $ 1,257 $ 160,935,648 $ (135,407,723) $ 25,588,742
Issuance of shares of common stock in underwritten public offering, net of offering costs 15,180,000 15,180 — 35,412,783 — 35,427,963
Exercise of stock options and warrants 25,071 25 — 18,110 — 18,135
Restricted Stock Units vested during period 111,667 111 — (111) — —
Restricted Stock Units withheld for taxes (35,279) (35) — (93,834) — (93,869)
Shares purchased through employee stock purchase plan 58,336 58 — 132,852 — 132,910
Stock-based compensation — — 2,785,574 — 2,785,574
Net loss — — — (13,281,304) (13,281,304)
Balance, June 30, 2020 74,900,047 $ 74,899 1,257,143 $ 1,257 $ 199,191,022 $ (148,689,027) $ 50,578,151


	Common stock			Preferred Stock			Additional paid-in		Accumulated		Total stockholders’
	Shares	Amount		Shares	Amount		capital		deficit		equity
Three Months Ended September 30, 2020
Balance, June 30, 2020	74,900,047	$	74,899	1,257,143	$	1,257	$	199,191,022	$	(148,689,027)	$	50,578,151
Stock-based compensation		—			—		1,447,531		—		1,447,531
Net loss		—			—		—		$	(13,458,645)	(13,458,645)
Balance, September 30, 2020	74,900,047	$	74,899	1,257,143	$	1,257	$	200,638,553	$	(162,147,672)	$	38,567,037


	Common stock			Preferred Stock			Additional paid-in		Accumulated		Total stockholders’
	Shares	Amount		Shares	Amount		capital		deficit		equity
Nine Months Ended September 30, 2020
Balance, December 31, 2019	44,384,222	$	44,384	2,857,143	$	2,857	$	135,238,941	$	(114,290,617)	$	20,995,565
Conversion of preferred stock to common stock	8,000,000	8,000		(1,600,000)	(1,600)		(6,400)		—		0
Issuance of shares related to Aevi Merger	3,893,361	3,894			—		15,491,684		—		15,495,578
Issuance of shares pursuant to registered direct offering, net of offering costs	1,306,282	1,306			—		5,134,878		—		5,136,184
Issuance of shares pursuant to common stock private placement, net of offering costs	1,951,219	1,951			—		3,886,040		—		3,887,991
Issuance of shares of common stock in underwritten public offering, net of offering costs	15,180,000	15,180			—		35,412,783		—		35,427,963
Exercise of stock options and warrants	50,239	50			—		92,292		—		92,342
Restricted Stock Units vested during period	111,667	111			—		(111)		—		0
Restricted Stock Units withheld for taxes	(35,279)	(35)			—		(93,834)		—		(93,869)
Shares purchased through employee stock purchase plan	58,336	58			—		132,852		—		132,910
Stock-based compensation		—			—		5,349,428		—		5,349,428
Net loss		—			—		—		$	(47,857,055)	(47,857,055)
Balance, September 30, 2020	74,900,047	$	74,899	1,257,143	$	1,257	$	200,638,553	$	(162,147,672)	$	38,567,037

Table of Contents

Common stock Preferred Stock Additional paid-in Accumulated Total stockholders’
Shares Amount Shares Amount capital deficit equity
Six Months Ended June 30, 2020
Balance, December 31, 2019 44,384,222 $ 44,384 2,857,143 $ 2,857 $ 135,238,941 $ (114,290,617) $ 20,995,565
Conversion of preferred stock to common stock 8,000,000 8,000 (1,600,000) (1,600) (6,400) — —
Issuance of shares related to Aevi Merger 3,893,361 3,894 — 15,491,684 — 15,495,578
Issuance of shares pursuant to registered direct offering, net of offering costs 1,306,282 1,306 — 5,134,878 — 5,136,184
Issuance of shares pursuant to common stock private placement, net of offering costs 1,951,219 1,951 — 3,886,040 — 3,887,991
Issuance of shares of common stock in underwritten public offering, net of offering costs 15,180,000 15,180 — 35,412,783 — 35,427,963
Exercise of stock options and warrants 50,239 50 — 92,292 — 92,342
Restricted Stock Units vested during period 111,667 111 — (111) — —
Restricted Stock Units withheld for taxes (35,279) (35) — (93,834) — (93,869)
Shares purchased through employee stock purchase plan 58,336 58 — 132,852 — 132,910
Stock-based compensation — — 3,901,897 — 3,901,897
Net loss — — — (34,398,410) (34,398,410)
Balance, June 30, 2020 74,900,047 $ 74,899 1,257,143 $ 1,257 $ 199,191,022 $ (148,689,027) $ 50,578,151


	Common stock			Preferred Stock			Additional paid-in		Accumulated		Total stockholders’
	Shares	Amount		Shares	Amount		capital		deficit		equity
Three Months Ended September 30, 2019
Balance, June 30, 2019	42,898,251	$	42,898	2,857,143	$	2,857	$	129,545,721	$	(111,895,217)	$	17,696,259
Issuance of shares pursuant to common stock private placement, net of offering costs	1,200,000	1,200			—		3,736,200		—		3,737,400
Exercise of stock options and warrants	539	1			—		1,175		—		1,176
Restricted Stock Units vested during period	11,250	11			—		(11)		—		0
Restricted Stock Units withheld for taxes	(3,246)	(3)			—		(15,898)		—		(15,901)
Stock-based compensation		—			—		818,794		—		818,794
Net loss		—			—		—		(4,016,454)		(4,016,454)
Balance, September 30, 2019	44,106,794	$	44,107	2,857,143	$	2,857	$	134,085,981	$	(115,911,671)	$	18,221,274

~~Table of Contents~~

Common stock Preferred Stock Additional paid-in Accumulated Total stockholders’
Shares Amount Shares Amount capital deficit equity
Three Months Ended June 30, 2019
Balance, March 31, 2019 42,753,659 $ 42,754 2,857,143 $ 2,857 $ 128,747,037 $ (105,672,118) $ 23,120,530
Exercise of stock options and warrants 43,125 43 — 162,596 — 162,639
Restricted Stock Units vested during period 61,250 61 — (61) — —
Restricted Stock Units withheld for taxes (3,723) (4) — (18,053) — (18,057)
Shares purchased through employee stock purchase plan 43,940 44 — 127,493 — 127,537
Stock-based compensation — — 526,709 — 526,709
Net loss — — — (6,223,099) (6,223,099)
Balance, June 30, 2019 42,898,251 $ 42,898 2,857,143 $ 2,857 $ 129,545,721 $ (111,895,217) $ 17,696,259


		Common stock					Preferred Stock						Additional paid-in				Accumulated			Total stockholders’			Common stock					Preferred Stock					Additional paid-in	Accumulated	Total stockholders’
		Shares	Amount		Shares		Amount		capital		deficit		equity			Shares		Amount			Shares			Amount		capital			deficit		equity
Six Months Ended June 30, 2019
Nine Months Ended September 30, 2019															Nine Months Ended September 30, 2019
Balance, December 31, 2018	Balance, December 31, 2018	40,804,189	$	40,804	$	2,857,143	$	2,857	$	119,082,157	$	(98,218,070)	$	20,907,748	Balance, December 31, 2018	40,804,189		$	40,804		$	2,857,143		$	2,857	$	119,082,157		$	(98,218,070)	$	20,907,748
Issuance of shares of common stock in underwritten public offering, net of offering costs	Issuance of shares of common stock in underwritten public offering, net of offering costs	1,818,182	1,818				—		8,974,142		—		8,975,960		Issuance of shares of common stock in underwritten public offering, net of offering costs	1,818,182		1,818						—		8,974,142			—		8,975,960
Issuance of shares pursuant to common stock private placement, net of offering costs															Issuance of shares pursuant to common stock private placement, net of offering costs	1,200,000		1,200						—		3,736,200			—		3,737,400
Exercise of stock options and warrants	Exercise of stock options and warrants	74,413	74				—		256,742		—		256,816		Exercise of stock options and warrants	74,952		75						—		257,918			—		257,993
Restricted Stock Units vested during period	Restricted Stock Units vested during period	161,250	162				—		(162)		—		—		Restricted Stock Units vested during period	172,500		173						—		(173)			—		0
Restricted Stock Units withheld for taxes	Restricted Stock Units withheld for taxes	(3,723)	(4)				—		(18,053)		—		(18,057)		Restricted Stock Units withheld for taxes	(6,969)		(7)						—		(33,952)			—		(33,959)
Shares purchased through employee stock purchase plan	Shares purchased through employee stock purchase plan	43,940	44				—		127,493		—		127,537		Shares purchased through employee stock purchase plan	43,940		44						—		127,493			—		127,537
Stock-based compensation	Stock-based compensation		—				—		1,123,402		—		1,123,402		Stock-based compensation			—						—		1,942,196			—		1,942,196
Net loss	Net loss		—				—		—		(13,677,147)		(13,677,147)		Net loss			—						—		—			(17,693,601)		(17,693,601)
Balance, June 30, 2019		42,898,251	$	42,898	$	2,857,143	$	2,857	$	129,545,721	$	(111,895,217)	$	17,696,259
Balance, September 30, 2019															Balance, September 30, 2019	44,106,794		$	44,107		$	2,857,143		$	2,857	$	134,085,981		$	(115,911,671)	$	18,221,274

See accompanying notes to the unaudited condensed consolidated financial statements.

109

Table of Contents

CERECOR INC. and SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements

1. Business

Cerecor Inc. (the "Company" or "Cerecor") is a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare ~~pediatric~~ and orphan diseases. The Company is advancing ~~an emerging~~its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare ~~pediatric~~ and orphan diseases. The Company's ~~pediatric~~ rare disease pipeline includes CERC-801, CERC-802 and CERC-803 ("CERC-800 compounds"), which are therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation ("CDGs"). The U.S. Food and Drug Administration ("FDA") granted Rare Pediatric Disease Designation ("RPDD") and Orphan Drug Designation ("ODD") to all 3 CERC-800 compounds, thus potentially qualifying the Company to receive a Priority Review Voucher ("PRV") upon approval of each new drug application ("NDA"). The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes) monoclonal antibody being developed for ~~the treatment of~~ COVID-19 acute respiratory distress syndrome ~~("ARDS")~~ and ~~Pediatric-onset~~for severe pediatric-onset Crohn's ~~Disease.~~disease. CERC-006 is a dual mTOR inhibitor being developed for the treatment of complex ~~Lymphatic Malformations~~lymphatic malformations and has been granted ODD and RPDD by the FDA, thus potentially qualifying the Company to receive a fourth PRV upon approval of an NDA. CERC-007 is an anti-IL-18 monoclonal antibody being developed for the treatment of autoimmune inflammatory diseases such as ~~Adult Onset Stills Disease ("AOSD")~~adult onset Still's disease and ~~Multiple Myeloma.~~multiple myeloma.

The Company continues to explore strategic alternatives for its commercialized product, Millipred^®, an oral prednisolone indicated across a wide variety of inflammatory ~~conditions. The Company has been in discussions with Simon Pedder, a former member of its Board of Directors, about potentially transferring~~conditions, and for its non-core neurology pipeline ~~assets, CERC-301 and CERC-406, to a new company formed by Dr. Pedder, although it has not agreed to binding terms, and any such transaction might not happen until the second half of 2020, if at all.~~assets.

On June 11, 2020, the Company closed on an underwritten public offering of 15,180,000 shares of its common stock (inclusive of 1,980,000 shares that were sold pursuant to the underwriter’s full exercise of its option to purchase additional shares of Cerecor’s common stock) for net proceeds of approximately $35.4 million.

On February 3, 2020, the Company ~~consummated~~closed on its ~~two-step~~ merger (the "Merger" or the "Aevi Merger") with Aevi Genomic Medicine, Inc. ("Aevi"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the "Merger Agreement") dated December 5, 2019. The Merger consideration included stock valued at approximately $15.5 million, resulting in the issuance of approximately 3.9 million shares of Cerecor common stock to Aevi stockholders, forgiveness of a $4.1 million loan that Cerecor loaned Aevi in December 2019 (the "Aevi Loan"), and contingent value rights ("CVRs") for up to an additional $6.5 million in subsequent payments based on development milestones. As part of the Merger,which Cerecor acquired the rights to CERC-002, CERC-006 and ~~CERC-007, expanding~~CERC-007. Additionally, certain members of Aevi's leadership joined Cerecor's ~~pipeline to six clinical stage assets being developed for rare pediatric~~management and ~~orphan diseases. Effective upon the consummation~~board of ~~the Merger, Cerecor entered into an employment agreement with Aevi Chief Executive Officer~~directors, most notably Mike Cola, ~~for him to serve as Cerecor's~~ Chief Executive ~~Officer and an employment agreement with Aevi Chief Scientific~~ Officer, Dr. Garry Neil, ~~for him to serve as Cerecor's~~ Chief ~~Medical~~Scientific Officer ~~and appointed Mike Cola~~ and Dr. Sol Barer, toChairman of the ~~Company's Board of Directors. Dr. Neil was promoted to Cerecor's Chief Scientific Officer in March 2020.~~Board. See Note 6 for more information.

During the fourth quarter of 2019, the Company entered into, and closed, an asset purchase agreement (the "Aytu Purchase Agreement") with Aytu BioScience, Inc. (“Aytu”) to sell the Company’s rights, title and interest in, assets relating to its pediatric portfolio, namely Aciphex^®~~Sprinkle™, Cefaclor for Oral Suspension, Karbinal™ ER, Flexichamber™, Poly-Vi-Flor~~^® and Tri-Vi-Flor™ (the "Pediatric Portfolio"), as well as the corresponding commercial infrastructure consisting of the right to offer employment to Cerecor’s sales force and the assignment of supporting commercial contracts (the "Aytu Divestiture"). Aytu paid consideration of $4.5 million in cash and approximately 9.8 million shares of Aytu convertible preferred stock (the "Investment"), and assumed certain of the Company’s liabilities, including the Company’s payment obligations payable to Deerfield CSF, LLC of $15.1 million and other liabilities of $11.0 million. The Company recognized a gain of $8.0 million upon the closing of the Aytu Divestiture for the year ended December 31, 2019. As a result of the sale of the Pediatric Portfolio, the Pediatric Portfolio met all conditions required in order to be classified as discontinued operations. Therefore, operating results from the Pediatric Portfolio are reported within income (loss) from discontinued operations, net of tax for all periods presented. In addition, assets and liabilities related to the Pediatric Portfolio are reported as assets and liabilities of discontinued operations in the accompanying condensed consolidated balance sheets as of June 30, 2020 and December 31, 2019. See Note 3 for more information regarding the Aytu Divestiture and its accounting treatment, including the nature of the Company's involvement subsequent to the divestiture.

~~Table of Contents~~

Cerecor was incorporated and commenced operation in 2011 and completed its initial public offering in October 2015.

Liquidity

In June 2020, the Company closed an underwritten public offering of 15,180,000 shares of its common stock (inclusive of 1,980,000 shares that were sold pursuant to the underwriter’s full exercise of its option to purchase additional shares of Cerecor’s common stock) for net proceeds of approximately $35.4 million. In March 2020, the Company entered into a securities purchase agreement with its largest stockholder, Armistice Capital, LLC ("Armistice"), pursuant to which the Company sold 1,951,219 shares of the Company’s common stock for net proceeds of approximately $3.9 million. In February 2020, the Company closed a registered direct offering with institutional investors of 1,306,282 shares of the Company's common stock for net proceeds of approximately $5.1 million. See Note 9 for more information regarding these financings. Additionally, in April 2020, the Company converted its shares of Aytu preferred stock that were acquired in the fourth quarter of 2019 ~~and subsequently sold that~~to Aytu common stock, which ~~generated~~it subsequently sold for net proceeds of approximately $12.8 million. As of ~~June~~September 30, 2020, Cerecor had ~~$45.4~~$33.4 million in cash and cash equivalents.

In order to meet its cash flow needs, the Company applies a disciplined decision-making methodology as it evaluates the optimal allocation of the Company's resources between investing in the Company's existing pipeline assets and acquisitions or in-licensing of new assets. For the ~~six~~nine months ended ~~June~~September 30, 2020, Cerecor generated a net loss of ~~$34.4~~$47.9 million and negative cash ~~flow~~flows from operations of ~~$14.3~~$26.2 million. As of ~~June~~September 30, 2020, Cerecor had an accumulated deficit of ~~$148.7~~$162.1 million.

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern; however, the Company expects to incur additional losses in the future in connection with its research and development activities and will require additional financing to fund its operations and to continue to execute its business strategy. The Company plans to use its current cash on hand, the anticipated cash flows from the Company's profits from Millipred product sales and/or the potential proceeds from a possible out-license or sale of Millipred to a third party to offset costs related to development of its pipeline assets, business development, and costs associated with its organizational infrastructure; however, Cerecor expects to continue to incur significant expenses and operating losses for the immediate future as it continues to invest in the Company's pipeline assets. The Company’s ability to continue as a going concern is dependent upon the Company’s ability to raise additional equity and/or debt capital, sell non-core assets and/or obtain government funding; however, there can be no assurance that it will be able to do so nor that such activities will generate sufficient amounts, if any, on terms acceptable to the Company.

Over the long term, the

Table of Contents

Company's ultimate ability to achieve and maintain profitability will ~~be dependent~~depend on, among other things, the development, regulatory approval, and commercialization of its pipeline assets, and the potential receipt and sale of any PRVs it receives, in order to support its cost structure and pipeline asset development.

These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements included in this Quarterly Report were issued. To alleviate these conditions, the Company is evaluating the potential out-licensing or sale of Millipred, its non-core ~~neurology~~ pipeline assets, ~~and/or some combination~~sale of rights to any future ~~PRV sales,~~issued PRVs, equity or debt financings, collaborations, other out-licensing arrangements, strategic alliances, federal and private grants, marketing, other distribution or licensing arrangements, or the sale of current or future assets. If the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company might have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible or suspend or curtail planned programs. Due to the uncertainty regarding future financings ~~and/or~~and other potential options to raise additional funds, management has concluded that substantial doubt exists with respect to the Company’s ability to continue as a going concern within one year after the date that the financial statements in this Quarterly Report were issued.

2. Basis of Presentation and Significant Accounting Policies

Basis of Presentation

The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates ("ASU") of the Financial Accounting Standards Board ("FASB").

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company’s financial position, results of operations, and cash flows. The condensed consolidated balance sheet at December 31, 2019 has been derived from audited

~~Table of Contents~~

financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission ("SEC"). ~~Certain prior period amounts have been reclassified to conform to the current year presentation, as described below.~~

The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the December 31, 2019 audited consolidated financial statements.

Significant Accounting Policies

During the ~~six~~nine months ended ~~June~~September 30, 2020, there were no significant changes to the Company’s summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC on March 11, 2020, except for the policy related to the Payroll Protection Program Loan and the recently adopted accounting standards described below.

Payroll Protection Program Loan

The Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") provides stimulus measures, including the Payroll Protection Loan Program ("PPP"), to provide certain small businesses with liquidity to support their operations (such as to retain employees and maintain payroll and lease payments) during the COVID-19 pandemic. Cerecor received a $0.4 million PPP Loan during the second quarter of 2020. PPP Loans have a 1% fixed annual interest rate and mature in two years, however are eligible for forgiveness under certain conditions. If there is reasonable assurance that the PPP Loan will be forgiven, the Company may elect to account for the loan either as debt under ASC 470 or as a government grant. If accounted for as a government grant, the Company may elect to present the loan as either a credit in the income statement within other income or as a reduction to the related expense. As discussed in Note 14, as of ~~June~~September 30, 2020, the Company believes it meets the criteria for forgiveness including having incurred the related expenses ~~prior to June 30,~~during the second quarter of 2020. Therefore, the Company elected to recognized the PPP Loan as other income within the accompanying condensed consolidated statement of operations for the ~~three and six~~nine months ended ~~June~~September 30, 2020.

Recently Adopted Accounting Pronouncements

Table of Contents

Financial Instruments - Credit Losses

In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13"). This guidance applies to all entities and impacts how entities account for credit losses for most financial assets and other instruments. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction to the carrying value of the asset. For trade receivables, loans and held-to-maturity debt securities, entities will be required to estimate lifetime expected credit losses. This guidance is effective for fiscal years beginning after December 15, 2019 and interim periods therein.

Upon adoption of the new standard on January 1, 2020, the Company began recognizing an allowance using a forward-looking approach to estimate the expected credit loss related to financial assets. The Company began monitoring the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in the customers’ credit profiles. Over 95% of sales were generated from three major industry wholesalers for the three and ~~six~~nine months ended ~~June~~September 30, 2020. Additionally, pursuant to the new standard, at each reporting period, the Company adjusts the Guarantee liability through earnings based on expected credit losses in accordance with Topic 326. The Company evaluated the impact of the adoption of this standard on its financial statements, concluding there was no significant impact on the Company's results of operations, financial position, cash flows or disclosures.

Fair Value Measurements

In August 2018, the FASB issued ASU No. 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement." This new standard modifies certain disclosure requirements on fair value measurements. This new standard became effective for the Company on January 1, 2020. The Company evaluated the impact of the adoption of this new standard on its financial statements, concluding there was no significant impact.

Income Tax Simplification

~~Table of Contents~~

In December 2019, the FASB issued ASU 2019-12, "Income Taxes (Topic 740)(ASU 2019-12)", which provides final guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation that is applicable to the Company, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences among other changes. For public business entities, the amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption of the amendments is permitted, including adoption in any interim period for public business entities for periods for which financial statements have not yet been issued. An entity that elects early adoption must adopt all the amendments in the same period. The Company elected to early adopt the ASU 2019-12 as of January 1, 2020. Management concluded that the adoption of the new standard did not have a material impact to income taxes reported on the financial statements for the three and ~~six~~nine months ended ~~June~~September 30, 2020.

3. Aytu Divestiture

Overview of Sale of Pediatric Portfolio and Related Commercial Infrastructure to Aytu BioScience

On October 10, 2019, the Company entered into the Aytu Purchase Agreement to sell the Company’s rights, title and interest in assets relating to its Pediatric Portfolio, namely Aciphex^®Sprinkle™, Cefaclor for Oral Suspension, Karbinal™ ER, Flexichamber™ , Poly-Vi-Flor^® and Tri-Vi-Flor™ (the "Pediatric Portfolio"), as well as the corresponding commercial infrastructure consisting of the right to offer employment to Cerecor’s sales force and the assignment of supporting commercial ~~contracts.~~contracts (the "Aytu Divestiture"). The Aytu Divestiture closed on November 1, 2019. Aytu paid consideration of $4.5 million in cash and approximately 9.8 million shares of Aytu convertible preferred stock, and assumed certain of the Company’s liabilities, including the Company’s payment obligations payable to Deerfield CSF, LLC of $15.1 million and certain other liabilities of $11.0 million primarily related to contingent consideration, Medicaid rebates and sales returns. The Company recognized a gain of $8.0 million upon the closing of the Aytu Divestiture for the year ended December 31, 2019. In addition, Aytu assumed future contractual obligations under existing license agreements associated with the Pediatric Portfolio. Armistice, a significant stockholder of the Company and Armistice's Chief Investment Officer, Steve Boyd, serves on each company's board of directors.

Upon ~~closing~~close of the Aytu Divestiture, Cerecor terminated all of its sales force personnel, which included those offered employment by Aytu, as well as any remaining sales force personnel. ~~Additionally,~~ Cerecor retained all rights to Millipred^®. Pursuant to a transition services agreement entered into between Aytu and Cerecor, Aytu is managing Millipred^®commercial operationsfor a

Table of Contents

monthly fee of $12,000 for up to 18 months or until the Company establishes an independent commercial infrastructure for the product.

Upon the sale of the Pediatric Portfolio to Aytu, the Pediatric Portfolio met all conditions to be classified as discontinued operations. Therefore, the accompanying condensed consolidated financial statements for the three and nine months ended September 30, 2020 and 2019 and as of December 31, 2019 reflect the operations, net of taxes, and related assets and liabilities of the Pediatric Portfolio as discontinued operations. Refer to the "Discontinued Operations" section below for more information, including Cerecor's continuing involvement.

Deerfield Guarantee

On November 1, 2019, in conjunction with the closing of the Aytu Divestiture, the Company entered into a Guarantee in favor of Deerfield CSF, LLC ("Deerfield"), which guarantees the payment by Aytu of the assumed liabilities to Deerfield, which includes the debt obligation ("Fixed Payment Guarantee") and the contingent consideration related to future potential royalties on Avadel's pediatric products ("Deferred Payment Guarantee"), collectively referred to as the "Guarantee". Additionally, on November 1, 2019, the Company entered into a Contribution Agreement with Armistice and Avadel that governs contribution rights and obligations of the Company, Armistice and Avadel with respect to amounts that are paid by Armistice and Avadel to Deerfield under certain guarantees made by Armistice and Avadel to Deerfield.

The debt obligation assumed by Aytu consists of fixed monthly payments to Deerfield of $0.1 million until January 2021 and an additional balloon payment of $15.0 million to Deerfield on January 31, 2021. ~~In May 2020,~~ Aytu publicly reported that it had paid the $15.0 million balloon payment to Deerfield before it came due in June 2020, thus satisfying that portion of the debt obligation assumed as part of the divestiture. ~~Therefore,~~ Cerecor's Fixed Payment Guarantee will end on January 31, 2021, upon the final monthly payment of $0.1 million. The contingent consideration assumed by Aytu consists of quarterly deferred payments equal to 15% of net sales of certain Pediatric Portfolio or at least $0.3 million paid in arrears each quarter until the earlier of (i) February 5, 2026, or (ii) when $12.5 million in aggregate deferred payments have been paid to Deerfield. Of the contingent consideration, $3.2 million was paid to Deerfield prior to the Aytu Divestiture and therefore as of November 1, 2019, Aytu was responsible for the remaining $9.3 million. Aytu is required to pay an amount equal to at least $0.1 million per month. Cerecor's Deferred Payment Guarantee will end upon the earlier of (i) February 5, 2026, or (ii) upon $12.5 million in aggregate deferred payments has been paid to Deerfield. Cerecor is required to make payment under the Guarantee upon demand by Deerfield, which Deerfield can demand at any time if all or any part of the fixed payments and/or deferred payments are not paid by Aytu when due or upon breach of a covenant. AsThe remaining minimum commitments payable as most recently publicly reported by Aytu was $7.3 million as of June 30, 2020, ~~the~~which represents Cerecor's estimated maximum potential ~~amount of~~ future payments under the ~~Guarantee was $9.0 million, consisting of $0.6 million for the Fixed Payment Guarantee and $8.4 million for the Deferred Payment Guarantee (utilizing the $0.3 million per quarter minimum payment).~~Guarantee.

~~Table of Contents~~

The fair value of the Guarantee, which relates to the Company's obligation to make future payments if Aytu defaults, was determined at the time of the divestiture as the difference between (i) the estimated fair value of the debt and contingent payments, respectively, using Cerecor's estimated cost of debt and (ii) the estimated fair value of the debt and contingent payments, respectively, using Aytu's estimated cost of debt. Subsequent to the close of the Aytu Divestiture, at each reporting period, the value of the Guarantee is determined based on the expected credit loss of the Guarantee with changes recorded in (loss) income from discontinued operations, net of tax within the consolidated statements of operations. In 2020, Aytu's credit rating significantly improved as a result of recent developments to Aytu's business, including but not limited to, recent financings and expansion of its revenue products that substantially enhanced Aytu's cash position and its ability to meet its financial commitments. Based on these facts, management concluded that the expected credit loss of the Guarantee was de minimis as of ~~March 31,~~September 30, 2020, ~~and June 30, 2020. Therefore,~~thus recognizing 0 change in value ~~was recognized~~ in income from discontinued operations, net of tax within the accompanying condensed consolidated statement of operations for the three months ended ~~June~~September 30, 2020 and a $1.8 million gain on the change in value ~~was recognized~~ in income from discontinued operations, net of tax within the accompanying condensed consolidated statement of operations for the ~~six~~nine months ended ~~June~~September 30, ~~2019.~~2020.

Discontinued Operations

As a result of the sale of the Pediatric Portfolio, the operating results from the Pediatric Portfolio are reported as (loss) income from discontinued operations, net of tax in the accompanying condensed consolidated statements of operations. Accordingly, the accompanying condensed consolidated financial statements for the three and six months ended June 30, 2020 and 2019 and as of December 31, 2019 reflect the operations and related assets and liabilities of the Pediatric Portfolio as a discontinued operation.

The following tables summarizes the assets and liabilities of the discontinued operations as of ~~June~~September 30, 2020 and December 31, 2019:

June 30, 2020 December 31,
(unaudited) 2019
Assets
Current assets:
Accounts receivable, net $ — $ 497,577
Total current assets of discontinued operations $ — $ 497,577
Liabilities
Current liabilities:
Accounts payable $ — $ 387,975
Accrued expenses and other current liabilities 5,549,751 3,503,037
Total current liabilities of discontinued operations 5,549,751 3,891,012
Other long-term liabilities — 1,755,000
Total long-term liabilities of discontinued operations $ — $ 1,755,000

Table of Contents


	September 30, 2020		December 31,
	(unaudited)		2019
Assets
Current assets:
Accounts receivable, net	$	0	$	497,577
Total current assets of discontinued operations	$	0	$	497,577

Liabilities
Current liabilities:
Accounts payable	$	0	$	387,975
Accrued expenses and other current liabilities	5,833,729		3,503,037
Total current liabilities of discontinued operations	5,833,729		3,891,012
Other long-term liabilities	0		1,755,000
Total long-term liabilities of discontinued operations	$	0	$	1,755,000

Cerecor retains continuing involvement with the divested Pediatric Portfolio related to future sales returns made after November 1, 2019 of sales of the Pediatric Portfolio prior to the close date of the Aytu Divestiture and the Deerfield ~~Guarantee (discussed in detail above).~~

Guarantee. Pursuant to the Aytu Purchase Agreement, Aytu assumed sales returns of the Pediatric Portfolio made after the closing date of November 1, 2019 and primarily relating to sales prior to November 1, 2019 only to the extent such post-Closing sales returns exceed $2.0 million and are less than $2.8 million (in other words, Aytu will only assume $0.8 million of such returns). Therefore, Cerecor is liable for future sales returns of the Pediatric Portfolio sold prior to November 1, 2019 in excess of the $0.8 million assumed by Aytu. As of ~~June~~September 30, 2020, the Company estimated its sales return reserve from discontinued operations to be ~~$1.6~~$1.5 million, which is included above in accrued expenses and other current liabilities from discontinued operations. Changes in the Company's estimate of sales returns related to the Pediatric Portfolio is included within discontinued operations on the statement of operations and is shown within product sales, net in the table summarizing the results of discontinued operations below. In future periods, as additional information becomes available to the Company, the Company expects to recognize expense (or a benefit) related to actual sales returns of the Pediatric Portfolio in excess (or less than) the returns reserve recorded, ~~as of November 1, 2019,~~ which will be recognized within discontinued operations. The Company expects this involvement to continue until sales returns are no longer accepted on sales of the Pediatric Portfolio made prior to November 1, 2019, which, in line with the products' return policies,

~~Table of Contents~~

returns on these products may be accepted through 2023. The remaining liability within accrued expenses and other liabilities of discontinued operations as of ~~June~~September 30, 2020 largely relates to cash Cerecor collected on behalf of Aytu for post-divestiture sales of the Pediatric Portfolio, which will be remitted to Aytu. The collection of accounts receivable from Cerecor to Aytu was fully transitioned to Aytu during the second quarter of 2020.

The following table summarizes the results of discontinued operations for the three and ~~six~~nine months ended ~~June~~September 30, 2020 and 2019:

Three Months Ended June 30, Six Months Ended June 30,
2020 2019 2020 2019
Product revenue, net $ (455,463) $ 3,057,462 $ (1,172,805) $ 5,892,537
Operating expenses:
Cost of product sales — 1,354,855 — 2,550,199
General and administrative — 41,374 — 82,747
Sales and marketing — 2,610,990 — 5,323,616
Amortization expense — 744,099 — 1,488,199
Impairment of intangible assets — 1,449,121 — 1,449,121
Change in fair value of contingent consideration — 284,800 — 444,261
Total operating expenses — 6,485,239 — 11,338,143
Other (expense) income:
Change in value of Guarantee — — 1,755,000 —
Interest expense, net — (238,158) — (476,316)
Total other (expense) income — (238,158) 1,755,000 (476,316)
(Loss) income from discontinued operations before tax (455,463) (3,665,935) 582,195 (5,921,922)
Income tax expense — 12,971 — 48,658
(Loss) income from discontinued operations, net of tax $ (455,463) $ (3,678,906) $ 582,195 $ (5,970,580)

Table of Contents


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	(unaudited)				(unaudited)
Product revenue, net	$	(197,505)	$	3,412,044	$	(1,370,310)	$	9,304,580

Operating expenses:
Cost of product sales	0		1,302,679		0		3,852,878
General and administrative	0		41,374		0		124,121
Sales and marketing	0		2,416,338		0		7,739,955
Amortization expense	0		702,665		0		2,190,865
Impairment of intangible assets	0		0		0		1,449,121
Change in fair value of contingent consideration	0		(197,219)		0		247,042
Total operating expenses	0		4,265,837		0		15,603,982
Other (expense) income:
Change in value of Guarantee	0		0		1,755,000		0
Interest expense, net	0		(238,158)		0		(714,473)
Total other (expense) income	0		(238,158)		1,755,000		(714,473)
(Loss) income from discontinued operations before tax	(197,505)		(1,091,951)		384,690		(7,013,875)
Income tax (benefit) expense	0		(5,989)		0		42,668
(Loss) income from discontinued operations, net of tax	$	(197,505)	$	(1,085,962)	$	384,690	$	(7,056,543)

The significant non-cash operating items from the discontinued operations for the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019 are contained below. There were no non-cash investing items from the discontinued operations for the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019.


		Six Months Ended June 30,							Nine Months Ended September 30,
		2020		2019			2020		2019
Operating activities	Operating activities					Operating activities
Amortization	Amortization	$	—	$	1,488,199	Amortization	$	0	$	2,190,865
Impairment of intangible assets	Impairment of intangible assets	—		1,449,121		Impairment of intangible assets	0		1,449,121
Stock-based compensation, excluding amount included within gain on sale of Pediatric Portfolio	Stock-based compensation, excluding amount included within gain on sale of Pediatric Portfolio	—		202,330		Stock-based compensation, excluding amount included within gain on sale of Pediatric Portfolio	0		313,790
Change in fair value of contingent consideration liability	Change in fair value of contingent consideration liability	—		444,261		Change in fair value of contingent consideration liability	0		247,042
Change in value of Guarantee	Change in value of Guarantee	(1,755,000)		—		Change in value of Guarantee	(1,755,000)		0

4. Revenue ~~from Contracts with Customers~~

The Company generates substantially all of its revenue from sales of prescription drugs to its customers. Revenue from sales of prescription drugs was ~~$1.3~~$1.1 million and ~~$1.4~~$2.1 million for the three months ended ~~June~~September 30, 2020 and 2019, respectively. Revenue from sales of prescription drugs was ~~$4.1~~$5.2 million and ~~$4.0~~$6.1 million for the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019, respectively.

As is typical in the pharmaceutical industry, the Company sells its prescription drugs in the United States primarily through wholesale distributors and a specialty contracted pharmacy. Wholesale distributors account for substantially all of the Company’s net

~~Table of Contents~~

product revenues and trade receivables. In addition, the Company earns revenue from sales of its prescription drugs directly to retail pharmacies. For the three months ended ~~June~~September 30, 2020, the Company’s three largest customers accounted for approximately ~~50%~~40%, ~~30%~~24%, and ~~18%~~34% of the Company's total net product revenues from sale of prescription drugs from continuing operations. For the ~~six~~nine months ended ~~June~~September 30, 2020, the Company’s three largest customers accounted for approximately ~~44%~~43%, ~~29%~~28%, and ~~26%~~ 27%of the Company's total net product revenues from sale of prescription drugs from continuing operations.

Table of Contents

During the third quarter of 2020, the Company received notice from Teva of its termination of the License and Supply Agreement, effective April 1, 2021. Cerecor will continue to have the right under the agreement to sell the existing inventory on hand at April 1, 2021 for a period of six months after such date. The Company is currently in negotiations with Teva to extend the term of the License and Supply Agreement, however there can be no guarantee that any such extension will be granted. Finally, the Company continues to explore strategic alternatives for this product.

5. Net Loss Per Share

The Company computes earnings per share ("EPS") using the two-class method. The two-class method of computing EPS is an earnings allocation formula that determines EPS for common stock and any participating securities according to dividends declared and participation rights in undistributed earnings. The Company has two classes of stock outstanding, common stock and preferred stock. The preferred stock was issued in December 2018, upon Armistice exercising warrants to acquire an aggregate of 2,857,143 shares of the Series B Convertible Preferred Stock ("convertible preferred stock"). The convertible preferred stock has the same rights and preferences as the Company’s common stock, other than being non-voting, and is convertible into shares of common stock on a 1-for-5 ratio. During the first quarter of 2020, Armistice converted 1.6 million shares of Series B Convertible Preferred Stock into 8.0 million shares of Cerecor's common stock. Under the two-class method, the convertible preferred stock is considered a separate class of stock for EPS purposes and therefore basic and diluted EPS is provided below for both common stock and preferred stock.

EPS for common stock and EPS for preferred stock is computed by dividing the sum of distributed earnings and undistributed earnings for each class of stock by the weighted average number of shares outstanding for each class of stock for the period. In applying the two-class method, undistributed earnings are allocated to common stock and preferred stock based on the weighted average shares outstanding during the period, which assumes the convertible preferred stock has been converted to common stock.

Diluted net (loss) income per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents include: (i) outstanding stock options and restricted stock units, which are included under the "treasury stock method" when dilutive; (ii) common stock to be issued upon the assumed conversion of the Company's unit purchase option (the "UPO") shares issued in 2015 to the underwriters of the Company's initial public offering ("IPO"), which are included under the "if-converted method" when dilutive; and ~~(iii)~~(ii) common stock to be issued upon the exercise of outstanding warrants, which are included under the "treasury stock method" when dilutive. Because the impact of these items is generally anti-dilutive during periods of net loss, there is no difference between basic and diluted loss per common share for periods with net losses. In periods of net loss, losses are allocated to the participating security only if the security has not only the right to participate in earnings, but also a contractual obligation to share in the Company's losses.

The following table sets forth the computation of basic and diluted net (loss) income per share of common stock and preferred stock for the three and ~~six~~nine months ended ~~June~~September 30, 2020 and 2019, which includes both classes of participating securities:


		Three Months Ended															Three Months Ended
		June 30, 2020															September 30, 2020
		Common stock						Preferred stock							Common stock				Preferred stock
		Continuing Operations		Discontinued Operations		Continuing Operations		Discontinued Operations			Continuing Operations		Discontinued Operations		Continuing Operations		Discontinued Operations
Numerator:	Numerator:									Numerator:
Allocation of undistributed net loss	Allocation of undistributed net loss	$	(11,659,008)	$	(414,027)	$	(1,166,833)	$	(41,436)	Allocation of undistributed net loss	$	(12,234,411)	$	(182,214)	$	(1,026,729)	$	(15,291)
Denominator:	Denominator:									Denominator:
Weighted average shares	Weighted average shares	62,806,926		62,806,926		1,257,143		1,257,143		Weighted average shares	74,900,047		74,900,047		1,257,143		1,257,143
Basic and diluted net loss per share	Basic and diluted net loss per share	$	(0.18)	$	(0.01)	$	(0.93)	$	(0.03)	Basic and diluted net loss per share	$	(0.16)	$	(0.01)	$	(0.82)	$	(0.01)

1716

Table of Contents


		Three Months Ended															Three Months Ended
		June 30, 2019															September 30, 2019
		Common stock						Preferred stock							Common stock				Preferred stock
		Continuing Operations		Discontinued Operations		Continuing Operations		Discontinued Operations			Continuing Operations		Discontinued Operations		Continuing Operations		Discontinued Operations
Numerator:	Numerator:									Numerator:
Allocation of undistributed net loss	Allocation of undistributed net loss	$	(1,907,520)	$	(2,758,276)	$	(636,673)	$	(920,630)	Allocation of undistributed net loss	$	(2,202,802)	$	(816,299)	$	(727,690)	$	(269,663)
Denominator:	Denominator:									Denominator:
Weighted average shares	Weighted average shares	42,801,045		42,801,045		2,857,143		2,857,143		Weighted average shares	43,244,481		43,244,481		2,857,143		2,857,143
Basic and diluted net loss per share	Basic and diluted net loss per share	$	(0.05)	$	(0.06)	$	(0.23)	$	(0.32)	Basic and diluted net loss per share	$	(0.05)	$	(0.02)	$	(0.26)	$	(0.09)


		Six Months Ended															Nine Months Ended
		June 30, 2020															September 30, 2020
		Common stock						Preferred stock							Common stock				Preferred stock
		Continuing Operations		Discontinued Operations		Continuing Operations		Discontinued Operations			Continuing Operations		Discontinued Operations		Continuing Operations		Discontinued Operations
Numerator:	Numerator:									Numerator:
Allocation of undistributed net (loss) income	Allocation of undistributed net (loss) income	$	(31,098,910)	$	517,591	$	(3,881,695)	$	64,604	Allocation of undistributed net (loss) income	$	(43,510,912)	$	346,965	$	(4,730,833)	$	37,725
Denominator:	Denominator:									Denominator:
Weighted average shares	Weighted average shares	58,370,843		58,370,843		1,457,143		1,457,143		Weighted average shares	63,920,795		63,920,795		1,389,990		1,389,990
Basic and diluted net (loss) income per share	Basic and diluted net (loss) income per share	$	(0.53)	$	0.01	$	(2.66)	$	0.04	Basic and diluted net (loss) income per share	$	(0.68)	$	0.00	$	(3.40)	$	0.02


		Six Months Ended															Nine Months Ended
		June 30, 2019															September 30, 2019
		Common stock						Preferred stock							Common stock				Preferred stock
		Continuing Operations		Discontinued Operations		Continuing Operations		Discontinued Operations			Continuing Operations		Discontinued Operations		Continuing Operations		Discontinued Operations
Numerator:	Numerator:									Numerator:
Allocation of undistributed net loss	Allocation of undistributed net loss	$	(5,752,395)	$	(4,456,606)	$	(1,954,172)	$	(1,513,974)	Allocation of undistributed net loss	$	(7,958,896)	$	(5,279,871)	$	(2,678,162)	$	(1,776,672)
Denominator:	Denominator:									Denominator:
Weighted average shares	Weighted average shares	42,052,100		42,052,100		2,857,143		2,857,143		Weighted average shares	42,453,928		42,453,928		2,857,143		2,857,143
Basic and diluted net loss per share	Basic and diluted net loss per share	$	(0.14)	$	(0.10)	$	(0.68)	$	(0.53)	Basic and diluted net loss per share	$	(0.19)	$	(0.12)	$	(0.94)	$	(0.62)

The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the three months ended ~~June~~September 30, 2020 and 2019, as they could have been anti-dilutive:


		Three and Six Months Ended				Three and Nine Months Ended
		June 30,				September 30,
		2020	2019		2020	2019
Stock options	Stock options	9,363,265	5,476,547	Stock options	9,548,262	5,297,124
Warrants on common stock	Warrants on common stock	4,024,708	4,024,708	Warrants on common stock	4,024,708	4,024,708
Restricted Stock Units	Restricted Stock Units	155,833	278,750	Restricted Stock Units	155,833	267,500
Underwriters' unit purchase option		40,000	40,000

6. Asset Acquisition

Aevi Merger

On February 3, 2020, the Company consummated its two-step merger with Aevi, in accordance with the terms of the Merger Agreement dated December 5, 2019, by and between Cerecor, Genie Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Cerecor (“("Merger ~~Sub”~~Sub"), Second Genie Merger Sub, LLC (“("Second Merger ~~Sub”~~Sub"), a Delaware limited liability company

~~Table of Contents~~

and wholly owned subsidiary of Cerecor, and Aevi. On February 3, 2020, Merger Sub merged with and into Aevi, with Aevi as the

Table of Contents

surviving corporation, and as part of the same transaction, Aevi then merged with and into Second Merger Sub, with Second Merger Sub as the surviving entity. The surviving entity from the second merger was renamed Aevi Genomic Medicine, LLC and is disregarded as an entity separate from Cerecor for U.S. federal income tax purposes. Cerecor retained its public reporting and current NASDAQ listing status. Effective upon the ~~consummation~~close of the Merger, Cerecor entered into an employment agreement with ~~Aevi CEO~~Aevi's Chief Executive Officer, Mike Cola, for him to serve as Cerecor's Chief Executive Officer and an employment agreement with ~~Aevi CSO~~Aevi's Chief Scientific Officer, Dr. Garry Neil, for him to serve as Cerecor's Chief Medical Officer, and appointed ~~Mike~~Mr. Cola and Dr. Sol Barer to the Company's Board of Directors. Dr. Neil was promoted to Cerecor's Chief Scientific Officer in March 2020. Additionally, the Company extended employment agreements to seven other individuals who were previously employed by Aevi.

The ~~Merger~~merger consideration included stock valued at approximately $15.5 million, resulting in the issuance of approximately 3.9 million shares of Cerecor common stock to Aevi stockholders, forgiveness of a $4.1 million loan that Cerecor loaned Aevi in December 2019, contingent value rights for up to an additional $6.5 million in subsequent payments based on certain development milestones, payable in either shares of the Company's common stock or in cash at the election of the Company, and transaction costs of $1.5 million.

The fair value of the common stock transferred at closing was approximately $15.5 million using the Company's closing stock price on February 3, 2020. The assets acquired consisted primarily of $24.0 million of acquired in-process research and development ("IPR&D"), $0.3 million of cash and $0.7 million of assembled workforce. Refer to Note 7 for information regarding the valuation of the assembled workforce asset. The Company assumed net liabilities of $5.1 million. The Company recorded this transaction as an asset purchase as opposed to a business combination asbecause management concluded that substantially all the value received was related to one group of similar identifiable assets, which was the IPR&D for two early phase ~~therapies for rare and orphan diseases (CERC-006 and CERC-007).~~therapies. The Company considered these assets similar due to similarities in the risks of development, stage of development, regulatory pathway, patient populations and economics of commercialization. The fair value of the IPR&D was immediately recognized as acquired in-process research and development expense in the Company's consolidated statement of operations because the IPR&D asset has no alternate use due to the stage of development. The $1.5 million of transaction costs incurred were recorded to acquired IPR&D expense. The assembled workforce asset was recorded to intangible assets and will be amortized over an estimated useful life of two years.

~~The~~In addition to the issuance of Cerecor common stock, Cerecor agreed to pay contingent consideration of up to an additional $6.5 million ~~relates~~related to 2 future development milestones. The first milestone is the enrollment of a patient in a Phase II study related to CERC-002 for use in ~~Pediatric Onset~~pediatric onset Crohn's ~~Disease,~~disease, CERC-006 or CERC-007 prior to February 3, 2022. If this milestone is met, the Company is required to make a milestone payment of $2.0 million. The second milestone is the receipt of a NDA approval for either CERC-006 or CERC-007 from the FDA on or prior to February 3, 2025. If this milestone is met, the Company is required to make a milestone payment of $4.5 million. All milestones are payable in either shares of the Company's common stock or cash, at the election of the Company. The contingent consideration related to the development milestones will be recognized if and when such milestones are probable and can be reasonably estimated. As of the consummation of the Merger on February 3, 2020 and as of ~~June~~September 30, 2020, 0 contingent consideration related to the development milestone has been recognized. The Company will continue to monitor the development milestones at each reporting period.

7. Fair Value Measurements

ASC No. 820, Fair Value Measurements and Disclosures (“ASC 820”), defines fair value as the price that would be received to sell an asset, or paid to transfer a liability, in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value standard also establishes a three‑level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:

•Level 1—inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.

•Level 2—inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model‑derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.

•Level 3—inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability.

~~Table of Contents~~

The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company’s assets and liabilities that are measured at fair value on a recurring basis:


	~~June 30, 2020~~
	~~Fair Value Measurements Using~~
	~~Quoted prices in~~		~~Significant other~~		~~Significant~~
	~~active markets for~~		~~observable~~		~~unobservable~~
	~~identical assets~~		~~inputs~~		~~inputs~~
	~~(Level 1)~~		~~(Level 2)~~		~~(Level 3)~~
~~Assets~~
Investments in money market funds*	$	~~43,800,469~~	$	—	$	—
~~Investment in Aytu~~	$	—	$	—	$	—
~~Liabilities~~
Warrant liability**	$	—	$	—	$	20
Unit purchase option liability**	$	—	$	—	$	~~106~~

~~December 31, 2019~~

~~Fair Value Measurements Using~~

~~Quoted prices in~~

~~Significant other~~

~~Significant~~

~~active markets for~~

~~observable~~

~~unobservable~~

~~identical assets~~

~~inputs~~

~~(Level 1)~~

~~(Level 2)~~

~~(Level 3)~~

~~Assets~~

Investments in money market funds*

~~2,240,230~~

—

~~Investment in Aytu~~

—

~~7,628,947~~

—

~~Liabilities~~

Warrant liability**

—

~~3,460~~

Unit purchase option liability**

—

~~10,594~~

Table of Contents

September 30, 2020

Fair Value Measurements Using

Quoted prices in

Significant other

Significant

active markets for

observable

unobservable

identical assets

inputs

(Level 1)

(Level 2)

(Level 3)

Assets

Investments in money market funds*

32,465,053


	December 31, 2019
	Fair Value Measurements Using
	Quoted prices in		Significant other		Significant
	active markets for		observable		unobservable
	identical assets		inputs		inputs
	(Level 1)		(Level 2)		(Level 3)
Assets
Investments in money market funds*	$	2,240,230	$	0	$	0
Investment in Aytu	$	0	$	7,628,947	$	0

*Investments in money market funds are reflected in cash and cash equivalents on the accompanying condensed consolidated balance sheets.

**Warrant liability and UPO liability are reflected in accrued expenses and other current liabilities on the accompanying condensed consolidated balance sheets.

As of ~~June~~September 30, 2020 and December 31, 2019, the Company’s financial instruments included cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued expenses and other current ~~liabilities, warrant liability, and the underwriters' unit purchase option liability.~~liabilities. The carrying amounts reported in the accompanying condensed consolidated financial statements for cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses, and other current liabilities approximate their respective fair values because of the short-term nature of these accounts.

Level 2 Valuation

As part of the consideration for the Aytu Divestiture, Aytu issued to Cerecor 9,805,845 shares of Aytu Series G Convertible Preferred Stock (the "Aytu Series G Preferred Stock" or "Aytu Preferred Stock"). Subsequent to the initial measurement, at each reporting period, the Investment in Aytu was remeasured at the current fair value with the change in fair value recorded to other income, net in the accompanying statements of operations.

In April 2020, Cerecor was permitted to convert the Aytu Preferred Stock into 9,805,845 shares of Aytu’s common stock (the "Aytu Common Shares"), and subsequently sold all of the Aytu Common Shares in a series of transactions in April, pursuant to an effective registration statement, which generated net proceeds of approximately $12.8 million. The sale resulted in a realized gain of $5.2 million, which was recognized in change in fair value of Investment in Aytu within the accompanying condensed consolidated statement of operations for the ~~six~~nine months ended ~~June~~September 30, 2020.

Level 3 Valuation

~~Table of Contents~~

The ~~tables~~table presented below ~~are a~~is the summary of changes in the fair value of the Company’s Level 3 ~~valuations~~valuation for the ~~warrant liability, UPO liability and~~ contingent consideration for the ~~six~~nine months ended ~~June~~September 30, ~~2020 and 2019:~~2019.

Warrant Unit purchase Contingent
liability option liability consideration Total
Balance at December 31, 2019 $ 3,460 $ 10,594 $ — $ 14,054
Change in fair value (3,440) (10,488) — (13,928)
Balance at June 30, 2020 $ 20 $ 106 $ — $ 126

Warrant Unit purchase Contingent
liability option liability consideration Total
Balance at December 31, 2018 $ 2,950 $ 7,216 $ 1,256,210 $ 1,266,376
Change in fair value 8,570 20,098 (1,256,210) (1,227,542)
Balance at June 30, 2019 $ 11,520 $ 27,314 $ — $ 38,834


	Contingent
	consideration
Balance at December 31, 2018	$	1,256,210
Change in fair value	(1,256,210)
Balance at September 30, 2019	$	0

In 2014, the Company issued warrants to purchase 625,208 shares of convertible preferred stock. Upon the closing of the Company's initial public offering ("IPO") in October 2015, these warrants became warrants to purchase 22,328 shares of common stock, in accordance with their terms. The warrants expire in October 2020. The warrants represent a freestanding financial instrument that is indexed to an obligation, which the Company refers to as the warrant liability. The warrant liability is marked-to-market each reporting period with the change in fair value recorded to other income, net in the accompanying statements of operations until the warrants are exercised, expire or other facts and circumstances lead the warrant liability to be reclassified to stockholders’ equity. The fair value of the warrant liability is estimated using a Black-Scholes option-pricing model. The significant assumptions used in preparing the option pricing model for valuing the warrant liability as of June 30, 2020, include (i) volatility of 74.2%, (ii) risk free interest rate of 0.16%, (iii) strike price of $8.40, (iv) fair value of common stock of $2.60, and (v) expected life of 0.3 years.

The underwriters’ UPO was issued to the underwriters of the Company's IPO in 2015 and provides the underwriters the option to purchase up to a total of 40,000 units. The units underlying the UPO will be, immediately upon exercise, separated into shares of common stock, underwriters’ Class A warrants and underwriters’ Class B warrants (such warrants together referred to as the Underwriters’ Warrants). The Underwriters’ Warrants were warrants to purchase shares of common stock. The Class B warrants expired in April 2017 and the Class A warrants expired in October 2018, while the UPO expires in October 2020. The Company classifies the UPO as a liability, as it is a freestanding marked-to-market derivative instrument that is precluded from being classified in stockholders’ equity. The UPO liability is marked-to-market each reporting period with the change in fair value recorded to other income, net in the accompanying statements of operations until the UPO is exercised, expires or other facts and circumstances lead the UPO to be reclassified to stockholders’ equity. The fair value of the UPO liability is estimated using a Black-Scholes option-pricing model. The significant assumptions used in preparing the simulation model for valuing the UPO as of June 30, 2020, include (i) volatility of 74.2%, (ii) risk free interest rate of 0.16% , (iii) unit strike price of $7.47, (iv) fair value of underlying equity of $2.60, and (v) expected life of 0.3 years.

The Company's historical business acquisition of TRx Pharmaceuticals, LLC ("TRx") in November 2017 (the "TRx Acquisition") involved the potential for future payment of consideration that is contingent upon the achievement of operational and commercial milestones. The fair value of contingent consideration was determined at the acquisition date utilizing unobservable inputs

Table of Contents

such as the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the contingent consideration liabilities were remeasured at the current fair value with changes recorded in the consolidated statement of operations.

The consideration for the TRx Acquisition included certain potential contingent payments. First, pursuant to the TRx Purchase Agreement, the Company would have been required to pay $3.0 million to the sellers if the gross profit related to TRx products equaled or exceeded $12.6 million in 2018. The Company did not achieve this contingent event in 2018 and therefore 0 value was assigned to the contingent ~~payout as of December 31, 2018.~~payout. Additionally, pursuant to the TRx Purchase Agreement, the Company was required to pay the following: (1) $2.0 million upon the transfer of the Ulesfia NDA to the Company ("NDA Transfer Milestone"), and (2) $2.0 million upon FDA approval of a new dosage of Ulesfia ("FDA Approval Milestone"). However, as part of ~~the~~a settlement the Company entered into during the second quarter of 2019 with Lachlan Pharmaceuticals, an Irish company controlled by the previous owners of TRx, the Company gave up its right to sell Ulesfia, except for a limited amount of inventory on hand until that inventory is sold or expired. As a result, the settlement released the Company from the potential contingent payments related to the NDA Transfer Milestone and FDA Approval Milestone and therefore 0 value was assigned to the 2 milestones as of ~~June~~September 30, 2020 ~~or as of June 30,~~and 2019.

~~Table of Contents~~

Effective upon the consummation of the Aevi Merger during the first quarter of 2020, Cerecor entered into an employment agreement with ~~Aevi CEO~~Aevi's Chief Executive Officer, Mike Cola, for him to serve as Cerecor's Chief Executive Officer and an employment agreement with ~~Aevi CSO~~Aevi's Chief Scientific Officer, Dr. Garry Neil, for him to serve as Cerecor's Chief Medical Officer. Additionally, the Company extended employment agreements to seven other individuals who were previously employed by Aevi. As a result, the Company recognized an assembled workforce intangible asset of $0.7 million which is a Level 3 non-recurring fair value measurement. The Company utilized the replacement cost method to estimate the fair value of the assembled workforce, which considers the costs Cerecor would have incurred to replace a comparable workforce to the workforce acquired from Aevi. Such costs include, but are not limited to, recruiting costs, training costs and cost of lost productivity. The replacement costs were estimated based on a percentage of each employee's salary. The assembled workforce intangible asset will be amortized over a useful life of two years.

NaN other changes in valuation techniques or inputs occurred during the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019. NaN transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019.

8. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities as of ~~June~~September 30, 2020 and December 31, 2019 consisted of the following:

As of
June 30, 2020 December 31, 2019
Research and development expenses $ 1,899,830 $ 920,901
Compensation and benefits 1,670,669 1,591,964
General and administrative 912,943 360,016
Sales and marketing 212,807 120,056
Sales returns and allowances 1,144,427 2,284,175
Medicaid rebates 101,458 118,271
Lease liability, current 431,543 155,815
Other 113,981 89,054
Total accrued expenses and other current liabilities $ 6,487,658 $ 5,640,252

During the first quarter of 2020, the Company and an executive entered into a separation agreement in which the executive resigned his employment at the Company effective June 30, 2020. Following June 30, 2020, the former executive will receive continued payments of his base salary for a total of nine months, which resulted in an accrual of $0.3 million recognized in accrued expenses and other current liabilities on the Company's accompanying condensed consolidated balance sheet as of June 30, 2020 and is shown within the compensation and benefits line above.


	As of
	September 30, 2020		December 31, 2019
Research and development expenses	$	3,381,457	$	920,901
Compensation and benefits	2,431,358		1,591,964
General and administrative	705,867		360,016
Sales and marketing	142,000		120,056
Sales returns and allowances	1,520,716		2,284,175
Medicaid rebates	93,701		118,271
Lease liability, current	448,659		155,815
Other	86,964		89,054
Total accrued expenses and other current liabilities	$	8,810,722	$	5,640,252

~~Additionally, during~~During the second quarter of 2020, the Company and an executive entered into a separation agreement in which the executive resigned his employment effective April 24, 2020. The former executive serves as an advisor to the Company's Board of Directors and will continue to serve in such role until December 2021 or until terminated by either party upon thirty days' written notice. The former executive will receive $0.8 million in severance, which will be paid over 18 months beginning when his role as advisor to the Board ends. The ~~Company recognized a $0.8 million~~ severance ~~accrual~~liability, which is reported in other long-term liabilities on the Company's accompanying condensed consolidated balance sheet, is $0.8 million as of ~~June~~September 30, 2020.

9. Capital Structure

Table of Contents

According to the Company's amended and restated certificate of incorporation, the Company is authorized to issue 2 classes of stock, common stock and preferred stock. At ~~June~~September 30, 2020, the total number of shares of capital stock the Company was authorized to issue was 205,000,000 of which 200,000,000 was common stock and 5,000,000 was preferred stock. All shares of common and preferred stock have a par value of $0.001 per share.

On December 26, 2018, the Company filed a Certificate of Designation of Preferences of Series B Non-Voting Convertible Preferred Stock ("Series B Convertible Preferred Stock" or "convertible preferred stock") of Cerecor Inc. (the “Certificate of Designation of the Series B Preferred Stock”) classifying and designating the rights, preferences and privileges of the Series B Convertible Preferred Stock. The Certificate of Designation of the Series B Convertible Preferred Stock authorized 2,857,143 shares

~~Table of Contents~~

of convertible preferred stock. The Series B Convertible Preferred Stock converts to shares of common stock on a 1-for-5 ratio and has the same rights, preferences, and privileges as common stock other than it holds no voting rights.

Common Stock

June 2020 Financing

On June 11, 2020, the Company closed an underwritten public offering of 15,180,000 shares of its common stock (inclusive of 1,980,000 shares that were sold pursuant to the underwriter’s full exercise of its option to purchase additional shares of Cerecor’s common stock) for net proceeds of approximately $35.4 million. Armistice participated in the offering by purchasing 2,000,000 shares of common stock, on the same terms as all other investors. Additionally, certain of the Company's officers participated in the offering by purchasing an aggregate of 110,000 shares of common stock, on the same terms as all other investors.

March 2020 Financing

On March 17, 2020, the Company entered into a securities purchase agreement with Armistice pursuant to which the Company sold 1,951,219 shares of the Company’s common stock for net proceeds of approximately $3.9 million.

February 2020 Financing

On February 6, 2020, the Company closed a registered direct offering with certain institutional investors for the sale by the Company of 1,306,282 shares of the Company's common stock for net proceeds of approximately $5.1 million. Armistice participated in the offering by purchasing 1,256,282 shares of common stock from the Company, on the same terms as all other investors.

Aevi Merger

On February 3, 2020, under the terms of the Aevi Merger noted above in Note 6, the Company issued 3.9 million shares of common stock.

September 2019 Armistice Private Placement

On September 4, 2019, the Company entered into a securities purchase agreement with Armistice, pursuant to which the Company sold 1,200,000 shares of the Company’s common stock for net proceeds of approximately $3.7 million.

March 2019 Common Stock Offering

On March 8, 2019, the Company closed on an underwritten public offering of common stock for 1,818,182 shares of common stock of the Company for net proceeds of approximately $9.0 million. Armistice participated in the offering by purchasing 363,637 shares of common stock of the Company, on the same terms as all other investors.

Voting

The common stock is entitled to 1 vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors, and does not have cumulative voting rights. Accordingly, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election.

Dividends

Table of Contents

The holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by the board of directors out of legally available funds.

Liquidation

In the event of the Company’s liquidation, dissolution or winding up, holders of the Company’s common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all debts and other liabilities.

Rights and Preferences

~~Table of Contents~~

Holders of the Company’s common stock have 0 preemptive, conversion or subscription rights, and there are 0 redemption or sinking fund provisions applicable to the Company’s common stock.

Common Stock Warrants

At ~~June~~September 30, 2020, the following common stock warrants were outstanding:

Number of shares Exercise price Expiration
underlying warrants per share date
22,328* $ 8.40 October 2020
2,380* $ 8.68 May 2022
4,000,000 $ 12.50 June 2024
4,024,708

*Accounted for as a liability instrument (see Note 7)


Number of shares	Exercise price		Expiration
underlying warrants	per share		date
22,328	$	8.40	October 2020
2,380	$	8.68	May 2022
4,000,000	$	12.50	June 2024
4,024,708

Convertible Preferred Stock

December 2018 Armistice Private Placement

On December 27, 2018, the Company entered into a series of transactions as part of a private placement with its largest stockholder, Armistice, whose Chief Investment Officer, Steve Boyd, is a Cerecor director, in order to generate cash to continue to develop its pipeline assets and for general corporate purposes. The transactions are considered one transaction for accounting purposes. As part of the transaction, the Company exchanged common stock warrants issued on April 27, 2017 to Armistice for the purchase of up to 14,285,714 shares of the Company’s common stock at an exercise price of $0.40 per share (the "original warrants") for like-kind warrants to purchase up to 2,857,143 shares of the Company's newly designated Series B Convertible Preferred Stock with an exercise price of $2.00 per share (the "exchanged warrants"). Armistice immediately exercised the exchanged warrants and acquired an aggregate of 2,857,143 shares of the convertible preferred stock. Net proceeds of the transaction were approximately $5.7 million for the year ended December 31, 2018. In order to provide Armistice an incentive to exercise the exchanged warrants, the Company also entered into a securities purchase agreement with Armistice in December 2018 pursuant to which the Company issued warrants for 4,000,000 shares of common stock of the Company with a term of 5.5 years and an exercise price of $12.50 per share (the "incentive warrants").

During the first quarter of 2020, Armistice converted 1,600,000 shares of Series B Convertible Preferred Stock (of its 2,857,143 million shares of convertible preferred stock) into 8,000,000 shares of Cerecor's common stock.

Voting

Holders of the Company's convertible preferred stock are not entitled to vote.

Dividends

The holders of convertible preferred stock are entitled to receive dividends, if any, as may be declared from time to time by the board of directors out of legally available funds.

Liquidation

Table of Contents

In the event of the Company’s liquidation, dissolution or winding up, holders of the Company’s convertible preferred stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all debts and other liabilities.

Rights and Preferences

Each share of convertible preferred stock converts to shares of common stock on a 1-for-5 ratio. There are no other preemptive or subscription rights and there are 0 redemption or sinking fund provisions applicable to the Company’s common stock.

10. Stock-Based Compensation

~~Table of Contents~~

2016 Equity Incentive Plan

On April 5, 2016, the Company’s board of directors adopted the 2016 Equity Incentive Plan (the “2016 Plan”) as the successor to the 2015 Omnibus Plan (the “2015 Plan”). The 2016 Plan was approved by the Company’s stockholders and became effective on May 18, 2016 (the “2016 Plan Effective Date”). Upon the 2016 Plan Effective Date, the 2016 Plan reserved and authorized up to 600,000 additional shares of common stock for issuance, as well as 464,476 unallocated shares remaining available for grant of new awards under the 2015 Plan. An Amended and Restated 2016 Equity Incentive Plan (the "2016 Amended Plan") was approved by the Company's stockholders in May 2018, which increased the share reserve by an additional 1.4 million shares. A Second Amended and Restated 2016 Equity Incentive Plan (the "2016 Second Amended Plan") was approved by the Company's stockholders in August 2019, which increased the share reserve by an additional 850,000 shares. A Third Amended and Restated Equity Incentive Plan (the "2016 Third Amended Plan") was approved by the Company's stockholders in June 2020 which increased the share reserve by an additional 2,014,400 shares. During the term of the 2016 Third Amended Plan, the share reserve will automatically increase on the first trading day in January of each calendar year by an amount equal to 4% of the total number of outstanding shares of common stock of the Company on the last trading day in December of the prior calendar year. As of ~~June~~September 30, 2020, there were ~~3,464,032~~3,279,035 shares available for future issuance under the 2016 Third Amended Plan.

Option grants expire after ten years. Employee options typically vest over three or four years. Employees typically receive a new hire option grant, as well as an annual grant in the first or second quarter of each year. Options granted to directors typically vest over one or three years. Directors may elect to receive stock options in lieu of board compensation, which vest immediately. For stock options granted to employees and non-employee directors, the estimated grant date fair market value of the Company’s stock-based awards is amortized ratably over the individuals’ service periods, which is the period in which the awards vest. Stock-based compensation expense includes expense related to stock options, restricted stock units and employee stock purchase plan shares. The amount of stock-based compensation expense recognized for the three and ~~six~~nine months ended ~~June~~September 30, 2020 and 2019 was as follows:


		Three Months Ended June 30,						Six Months Ended June 30,							Three Months Ended September 30,				Nine Months Ended September 30,
		2020		2019		2020		2019			2020		2019		2020		2019
Research and development	Research and development	$	390,506	$	120,709	$	772,275	$	178,085	Research and development	$	384,041	$	176,261	$	1,156,317	$	354,347
General and administrative	General and administrative	2,307,998		196,211		2,987,598		665,336		General and administrative	971,558		473,905		3,959,156		1,139,241
Sales and marketing	Sales and marketing	87,070		56,823		142,024		77,651		Sales and marketing	91,932		57,168		233,955		134,819
Total stock-based compensation, continuing operations	Total stock-based compensation, continuing operations	2,785,574		373,743		3,901,897		921,072		Total stock-based compensation, continuing operations	1,447,531		707,334		5,349,428		1,628,407
Total stock-based compensation, discontinued operations	Total stock-based compensation, discontinued operations	—		152,966		—		202,330		Total stock-based compensation, discontinued operations	0		111,459		0		313,789
Total stock-based compensation	Total stock-based compensation	$	2,785,574	$	526,709	$	3,901,897	$	1,123,402	Total stock-based compensation	$	1,447,531	$	818,793	$	5,349,428	$	1,942,196

Stock options with service-based vesting conditions

The Company has granted awards that contain service-based vesting conditions. The compensation cost for these options is recognized on a straight-line basis over the vesting periods. A summary of option activity for the ~~six~~nine months ended ~~June~~September 30, 2020 is as follows:

Options Outstanding
Number of shares Weighted average exercise price per share Weighted average grant date fair value per share Weighted average remaining contractual term (in years)
Balance at December 31, 2019 4,180,606 $ 4.80 $ 2.67 7.9
Granted 5,165,956 $ 3.52 $ 2.24
Exercised (50,239) $ 1.84 $ 1.22
Forfeited (629,300) $ 3.26 $ 1.95
Expired (303,758) $ 5.30 $ 3.03
Balance at June 30, 2020 8,363,265 $ 4.13 $ 2.45 7.8
Exercisable at June 30, 2020 2,719,729 $ 4.67 $ 2.60 5.1

Table of Contents


	Options Outstanding
	Number of shares	Weighted average exercise price per share		Weighted average grant date fair value per share		Weighted average remaining contractual term (in years)
Balance at December 31, 2019	4,180,606	$	4.80	$	2.67	7.9
Granted	5,630,953	$	3.44	$	2.19
Exercised	(50,239)	$	1.84	$	1.22
Forfeited	(629,300)	$	3.26	$	1.95
Expired	(583,758)	$	5.42	$	3.02
Balance at September 30, 2020	8,548,262	$	3.99	$	2.39	7.9

Exercisable at September 30, 2020	2,729,880	$	4.45	$	2.49	4.9

In February 2020, the Company granted options to purchase 2.4 million shares of common stock as inducement option grants, pursuant to NASDAQ Listing Rule 5635(c)(4), to certain executives who joined the Company in connection with the Aevi Merger. In

~~Table of Contents~~

March 2020, our Chief Executive Officer entered into an amended employment agreement in which his base salary in cash was reduced from an annual rate of $450,000 to an annual rate of $35,568 (the "Reduction"). In consideration for the Reduction, on a quarterly basis, the Company grants stock options, which vest immediately (the "Salary Options"), for the purchase of a number of shares of the Company’s common stock with a total value (based on the Black-Scholes valuation methodology) based on a pro rata total annual value of $414,432 of the foregone salary. ~~Finally, in~~In April 2020, the Company granted options with service-based vesting conditions as part of its annual grant to employees.

The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. As of ~~June~~September 30, 2020, the aggregate intrinsic value of options outstanding was ~~$0.7~~$0.5 million. The aggregate intrinsic value of options currently exercisable as of ~~June~~September 30, 2020 was ~~$0.6~~$0.4 million. There were ~~844,978~~1,135,129 options that vested during the ~~six~~nine months ended ~~June~~September 30, 2020 with a weighted average exercise price of ~~$4.96~~$4.58 per share. The total grant date fair value of shares which vested during the ~~six~~nine months ended ~~June~~September 30, 2020 was ~~$2.3~~$2.9 million.

The Company recognized stock-based compensation expense of ~~$1.7~~$1.1 million and ~~$2.5~~$3.5 million related to stock options with service-based vesting conditions for the three and ~~six~~nine months ended ~~June~~September 30, 2020, respectively. At ~~June~~September 30, 2020, there was ~~$11.1~~$10.9 million of total unrecognized compensation cost related to unvested service-based vesting condition awards. The unrecognized compensation cost is expected to be recognized over a weighted-average period of ~~3.2~~3.1 years.

Stock options with market-based vesting conditions

The Company has granted options that contain market-based vesting conditions. The following table summarizes the Company's market-based option activity for the ~~six~~nine months ended ~~June~~September 30, 2020:


		Options Outstanding											Options Outstanding
		Number of shares	Weighted average exercise price per share		Weighted average remaining contractual term (in years)	Aggregate intrinsic value (1)			Number of shares	Weighted average exercise price per share		Weighted average remaining contractual term (in years)	Aggregate intrinsic value (1)
Balance at December 31, 2019	Balance at December 31, 2019	300,000	$	4.98	9.4			Balance at December 31, 2019	300,000	$	4.98	9.4
Granted	Granted	1,000,000	$	3.29	10			Granted	1,000,000	$	3.29	9.7
Forfeited	Forfeited	(300,000)						Forfeited	(300,000)
Balance at June 30, 2020		1,000,000	$	3.29	10
Balance at September 30, 2020								Balance at September 30, 2020	1,000,000	$	3.29	9.7

Exercisable at June 30, 2020		500,000				$	45,000
Exercisable at September 30, 2020								Exercisable at September 30, 2020	500,000				$	0

(1) The aggregate intrinsic value in the above table represents the total pre-tax amount that a participant would receive if the option had been exercised on the last day of the respective fiscal period. Options with a market value less than its exercise value are not included in the intrinsic value amount.

Table of Contents

During the second quarter of 2020, 300,000 unvested market-based stock options were forfeited as a result of the resignation of an executive during ~~the~~that quarter. The forfeiture resulted in the reversal of the full expense previously recognized to date on this award of $0.4 million, which was recorded to general and administrative expense for the ~~three and six~~nine months ended ~~June~~September 30, 2020.

On June 18, 2020, the Company granted its recently appointed Chairman of the Board an option to purchase 1,000,000 shares of Company common stock with market-based vesting conditions. 500,000 of the shares vested immediately on the date of grant with an exercise price of the closing stock price on the date of grant of $2.51. 250,000 of the shares vest upon the Company's common stock reaching a 50% premium to the stock price on June 18, 2020 and will have an exercise price of the stock at that time and 250,000 of the shares vest upon the Company's common stock reaching a 75% premium to the stock price on June 18, 2020 and will have an exercise price of stock at that time. Each vesting tranche represents a unique requisite service period and therefore the compensation cost for each vesting tranche is recognized on a straight-line basis over its respective vesting period.

The Company recognized stock-based compensation expense of ~~$0.5~~$0.3 million and ~~$0.6~~$0.9 million related to stock options with market-based vesting conditions for the three and ~~six~~nine months ended ~~June~~September 30, 2020, respectively, which includes the reversal of the former ~~Executive Chairman's~~executive's forfeited options and the expense related to the market-based options granted during the quarter. At ~~June~~September 30, 2020, there was ~~$0.7~~$0.4 million of total unrecognized compensation cost related to unvested market-based vesting conditions awards. This compensation cost is expected to be recognized over a weighted-average period of ~~0.7~~0.4 years.

~~Table of Contents~~

Stock-based compensation assumptions

The following table shows the assumptions used to compute stock-based compensation expense for stock options with service-based vesting conditions granted to employees and members of the board of directors under the Black-Scholes valuation model for the ~~six~~nine months ended ~~June~~September 30, 2020:


Service-based options
Expected dividend yield						—%0%
Expected volatility						69.9% - ~~79.9%~~79.0%
Expected life (in years)						1.75 - 6.25
Risk-free interest rate						0.19% - 1.48%

Restricted Stock Units

The Company has granted restricted stock units ("RSU") to certain employees. The Company measures the fair value of the restricted awards using the stock price on the date of the grant. The restricted shares typically vest annually over a four-year period beginning on the first anniversary of the award. The following table summarizes the Company's RSU activity for the ~~six~~nine months ended ~~June~~September 30, 2020:


		RSUs Outstanding					RSUs Outstanding
		Number of shares	Weighted average grant date fair value			Number of shares	Weighted average grant date fair value
Unvested RSUs at December 31, 2019	Unvested RSUs at December 31, 2019	267,500	$	4.92	Unvested RSUs at December 31, 2019	267,500	$	4.92
Granted		—
Vested	Vested	(111,667)	$	4.93	Vested	(111,667)	$	4.93
Unvested RSUs at June 30, 2020		155,833	$	4.91
Unvested RSUs at September 30, 2020					Unvested RSUs at September 30, 2020	155,833	$	4.91

The Company recognized ~~stock-based compensation~~ expense of ~~$0.6 million and~~ $0.8 million related to RSUs for the ~~three and six~~nine months ended ~~June~~September 30, 2020, respectively. At June 30, 2020, there was $43,202 of total unrecognized compensation cost related to the RSU grants. This compensation cost is expected to be recognized over a weighted-average period of 2.0 years.2020.

Employee Stock Purchase Plan

On April 5, 2016, the Company’s board of directors approved the 2016 Employee Stock Purchase Plan (the “ESPP”). The ESPP was approved by the Company’s stockholders and became effective on May 18, 2016 (the “ESPP Effective Date”).

Under the ESPP, eligible employees can purchase common stock through accumulated payroll deductions at such times as are established by the administrator. The ESPP is administered by the compensation committee of the Company’s board of directors. Under the ESPP, eligible employees may purchase stock at 85% of the lower of the fair market value of a share of the Company’s common stock (i) on the first day of an offering period or (ii) on the purchase date. Eligible employees may contribute up to 15% of

Table of Contents

their earnings during the offering period. The Company’s board of directors may establish a maximum number of shares of the Company’s common stock that may be purchased by any participant, or all participants in the aggregate, during each offering or offering period. Under the ESPP, a participant may not accrue rights to purchase more than $25,000 of the fair market value of the Company’s common stock for each calendar year in which such right is outstanding.

Upon the ESPP Effective Date, the Company reserved and authorized up to 500,000 shares of common stock for issuance under the ESPP. On January 1 of each calendar year, the aggregate number of shares that may be issued under the ESPP shall automatically increases by a number equal to the lesser of (i) 1% of the total number of shares of the Company’s capital stock outstanding on December 31 of the preceding calendar year, and (ii) 500,000 shares of the Company’s common stock, or (iii) a number of shares of the Company’s common stock as determined by the Company’s board of directors or compensation committee. The number of shares were increased by 443,842 on January 1, 2020. As of ~~June~~September 30, 2020, 1,504,388 shares remained available for issuance.

In accordance with the guidance in ASC 718-50, Employee Stock Purchase Plans, the ability to purchase shares of the

~~Table of Contents~~

Company’s common stock at the lower of the offering date price or the purchase date price represents an option and, therefore, the ESPP is a compensatory plan under this guidance. Accordingly, stock-based compensation expense is determined based on the option’s grant-date fair value and is recognized over the requisite service period of the option. The Company used the Black-Scholes valuation model and recognized stock-based compensation expense of ~~$54,590~~$0.1 million and ~~$0.1~~$0.2 million, respectively, for the three and ~~six~~nine months ended ~~June~~September 30, 2020.

11. Income Taxes

The Company recognized an income tax benefit of ~~$0.5 million and~~ $2.6 million for the ~~three and six~~nine months ended ~~June~~September 30, 2020 ~~respectively. The benefit recognized was~~due to a ~~result of a current year~~ tax law change ~~and~~resulting in the Company's ability ~~of the Company~~ to now carry back certain ~~losses due to the CARES Act.~~losses. The tax provisions within the CARES Act included temporary changes regarding the utilization and five year carry back of losses generated in 2018, 2019 and 2020, temporary changes regarding interest deductions, technical corrections from prior tax legislation related to qualified improvement property, and various other measures. In the second quarter of 2020, the Company filed a refund claim with the Internal Revenue Service related to its 2017 tax liability by carrying back losses not previously claimed. In June 2020, the state of Maryland issued a report announcing that the state decoupled from the CARES Act loss carryback provisions for the 2020 year only, but carrybacks are presently allowed under current law for 2018 and 2019. As a result, the Company recognized a $2.2 million benefitAdditionally, in the ~~first~~fourth quarter of 2020, ~~related to~~ the ~~federal tax carryback and an additional $0.5 million in the second quarter of 2020~~Company filed a refund claim related to the Maryland tax carryback. The ~~Company intends to file a claim related to the Maryland tax liability during the third quarter of 2020. The~~ expense recognized for the three and ~~six~~nine months ended ~~June~~September 30, 2019 of $0.1 million and ~~$0.2~~$0.3 million, respectively, was a result of interest on an unpaid tax liability related to the 2017 tax year and state taxes.

12. Leases

The Company currently occupies 2 leased properties, both of which serve as administrative office space. The Company determined that both leases are operating leases based on the lease classification test performed at lease commencement.

The annual base rent for the Company's ~~corporate headquarters~~office located in Rockville, Maryland ~~(the "Headquarters' Lease")~~ is $161,671, subject to annual 2.5% increases over the term of the lease. The applicable lease provided for a rent abatement for a period of 12 months following the Company's date of occupancy. The lease has an initial term of 10 years from the date the Company makes its first annual fixed rent payment, which occurred in January 2020. The Company has the option to extend the lease 2 times, each for a period of five years, and may terminate the lease as of the sixth anniversary of the first annual fixed rent payment, upon the payment of a termination fee. As of the lease commencement date, it was not reasonably certain that the Company will exercise the renewal periods or early terminate the lease and therefore the end date of the lease for accounting purposes is January 31, 2030. The Company entered into a sublease for additional administrative office space in Chesterbrook, Pennsylvania in May 2020 (the "Chesterbrook Lease"). The annual base rent ~~for~~under the Chesterbrook Lease is $280,185. The lease expires in November 2021. The weighted average remaining term of the operating leases at ~~June~~September 30, 2020 was 7.7 years.

Supplemental balance sheet information related to the leased property is as follows:


		As of							As of
		June 30, 2020		December 31, 2019			September 30, 2020		December 31, 2019
Property and equipment, net	Property and equipment, net	$	1,056,441	$	718,626	Property and equipment, net	$	983,411	$	718,626

Accrued expenses and other current liabilities	Accrued expenses and other current liabilities	$	431,543	$	155,815	Accrued expenses and other current liabilities	$	448,659	$	155,815
Other long-term liabilities	Other long-term liabilities	1,191,560		1,111,965		Other long-term liabilities	1,093,699		1,111,965
Total operating lease liabilities	Total operating lease liabilities	$	1,623,103	$	1,267,780	Total operating lease liabilities	$	1,542,358	$	1,267,780

Table of Contents

The operating lease right-of-use ("ROU") assets are included in property and equipment and the lease liabilities are included in accrued expenses and other current liabilities and other long-term liabilities in our condensed consolidated balance sheets. The Company utilized a weighted average discount rate of ~~7.2%~~7.3% to determine the present value of the lease payments.

The components of lease expense for the three and ~~six~~nine months ended ~~June~~September 30, 2020 and 2019 were as follows:

Three Months Ended June 30, Six Months Ended June 30,
2020 2019 2020 2019
Operating lease cost* $ 87,199 $ 39,534 $ 141,708 $ 94,140

~~Table of Contents~~


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Operating lease cost*	$	102,284	$	32,326	$	243,991	$	126,467

*Includes short-term leases, which are immaterial.

The following table shows a maturity analysis of the operating lease liability as of ~~June~~September 30, 2020:



		Undiscounted Cash Flows			Undiscounted Cash Flows
July 1, 2020 through December 31, 2020		$	220,689
October 1, 2020 through December 31, 2020				October 1, 2020 through December 31, 2020	$	111,474
2021	2021	426,346		2021	426,346
2022	2022	173,748		2022	173,748
2023	2023	178,092		2023	178,092
2024	2024	182,544		2024	182,544
2025	2025	187,108		2025	187,108
Thereafter	Thereafter	813,638		Thereafter	813,638
Total lease payments	Total lease payments	$	2,182,165	Total lease payments	$	2,072,950
Less implied interest	Less implied interest	(559,062)		Less implied interest	(530,592)
Total	Total	$	1,623,103	Total	$	1,542,358

13. Commitments and Contingencies

Litigation

Litigation - General

The Company may become party to various contractual disputes, litigation, and potential claims arising in the ordinary course of business. The Company currently does not believe that the resolution of such matters will have a material adverse effect on its financial position or results of operations except as otherwise disclosed in this report.

Settlement Agreement with Former TRx ~~2018 Target Gross Profit Dispute~~Owners

In November 2017, Cerecor acquired TRx in the TRx Acquisition. Immediately prior to the close of the TRx acquisition, TRx was owned by Fremantle LLC ("Fremantle") and LRS International, LLC ("LRS", and collectively, the "former TRx owners"). Various disputes and claims arose between Cerecor, including a member of Cerecor's board of directors (the "Cerecor Parties"), and the former TRx owners, which ultimately led to the parties entering into a settlement agreement on August 28, 2020. As part of the ~~TRx Acquisition, pursuant to the TRx Purchase Agreement, the Company was required to pay $3.0~~settlement agreement, Cerecor made a $0.9 million payment to the former TRx owners ifto settle all known disputes and claims between all parties. Additionally, the ~~gross profit, as defined in~~settlement agreement released all parties from other disputes and claims whether matured or unmatured and/or whether known or unknown from the ~~TRx Purchase Agreement, related to TRx products equaled or exceeded $12.6 million in 2018.~~beginning of time through the settlement date of August 28, 2020. The Company ~~believes it did not achieve this contingent event in 2018~~recognized the $0.9 million charge within general and ~~therefore, no amount is due to~~administrative expenses for the former TRx owners. However, during the second quarter of 2019, the former TRx owners disputed the Company's calculation of gross profit under the TRx Purchase Agreement, arguing the Company met the $12.6 million target in 2018. Pursuant to the TRx Purchase Agreement, the dispute was submitted to an independent accounting firm for resolution during the third quarter of 2019. The dispute was resolved on October 8, 2019, with the independent accounting firm ruling in favor of the Company.

~~However, on December 19, 2019, Cerecor received a letter from an attorney on behalf of the former TRx owners dated December 18, 2019 that enclosed a draft complaint seeking relief against Cerecor~~three and one of the members of its board of directors. The parties met for a pre-lawsuit mediation in June 2020, however no resolution was reached. As of the date of this filing, no lawsuit has been filed. The proposed complaint indicates that the former TRx owners would seek the following relief: (a) $3.0 million on the grounds that commercially reasonable efforts to sell the acquired TRx products would have resulted in the gross profit earn-out target being reached; (b) that the $3.0 million amount be trebled as a result of Cerecor's alleged improper conduct; (c) $9.2 million as a result of alleged losses resulting from the alleged improper treatment of the former TRx owners as affiliates; and (d) the removal of any restrictions on the former TRx owners shares of common stock in Cerecor. Cerecor disputes that the former TRx owners are entitled to the relief sought and intends to vigorously defend against any lawsuit filed on behalf of the former TRx owners. A loss in this matter is possible in a range of $0 to $18.2 million. As a loss in this matter is not considered probable, there has been no accrual recorded as of Junenine months ended September 30, 2020.

Karbinal Royalty Make-Whole Provision

On February 16, 2018, in connection with the acquisition of Avadel's pediatric products, the Company entered into a supply and distribution agreement with TRIS Pharma (the "Karbinal Agreement"). As part of this agreement, the Company had an annual minimum sales commitment, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units through 2033. The Company was required to pay TRIS a royalty make whole payment (“Make-Whole Payments”) of $30 for each unit under the 70,000 units annual minimum sales commitment through 2033.

Table of Contents

As a part of the Aytu Divestiture, which closed on November 1, 2019, the Company assigned all payment obligations, including the Make-Whole Payments, under the Karbinal Agreement (collectively, the "TRIS Obligations") to Aytu. However, under the original license agreement, the Company could ultimately be liable for TRIS Obligations to the extent Aytu fails to make the required payments. The future Make-Whole Payments to be made by Aytu are unknown as the amount owed to TRIS is dependent on the number of units sold.

~~Millipred License and Supply Agreement~~

The Company has a License and Supply Agreement for Millipred with Watson Laboratories, Inc., which is now part of Teva Pharmaceutical Industries Ltd. ("Teva"). Pursuant to the License and Supply Agreement, the Company is required to make license payments of $75,000 in February and August of each year through April 2021, and purchase inventory on an ad-hoc basis. The License and Supply Agreement expires on April 1, 2021, however if neither party terminates the agreement prior to April 1, 2021, then the agreement will automatically renew for successive one-year periods. Effective upon the consummation of the Merger, Cerecor appointed Dr. Sol Barer to the Company's Board of Directors. Dr. Barer also serves as Teva's Chairman of the Board.

Possible Future Milestone Proceeds for Out-Licensed Compounds

CERC-611 License Assignment

OnIn August 8, 2019, the Company entered into an assignment of license agreement (the "Assignment Agreement") with ES Therapeutics, LLC ("ES Therapeutics"), a wholly-owned subsidiary of Armistice, a significant stockholder of the Company. Pursuant to the Assignment Agreement, the Company assigned and transferred its rights, title, interest, and obligations with respect to CERC-611 to ES Therapeutics. The Company initially licensed the compound from Eli Lilly Company ("Lilly") in September 2016. Under the Assignment Agreement, Armistice paid the Company an upfront payment of $0.1 million. The Company recognized the payment as license and other revenue for the ~~year~~nine months ended ~~December 31,~~September 30, 2019. The Assignment Agreement also provides for: (a) a $7.5 million milestone payment to the Company upon cumulative net sales of licensed products reaching $750.0 million; and (b) a $12.5 million milestone payment to the Company upon cumulative net sales of licensed products reaching $1.3 billion. The Assignment Agreement ~~also~~ released the Company of obligations related to CERC-611, including the $1.3 million contingent payment to Lilly upon the first subject dosage of CERC-611 in a multiple ascending dose study. The Assignment Agreement also ~~releases~~released the Company from additional potential future payments due to Lilly upon achievement of certain development and commercialization milestones, including the first commercial sale, and milestone payments and royalty on net sales upon commercialization of the compound.

CERC-501 Sale to Janssen

In August 2017, the Company sold its worldwide rights to CERC-501 to Janssen Pharmaceuticals, Inc. ("Janssen") in exchange for initial gross proceeds of $25.0 million. There is a potential future $20.0 million regulatory milestone payment to the Company upon acceptance of an NDA for any indication. The terms of the agreement provide that Janssen will assume ongoing clinical trials and be responsible for any new development and commercialization of CERC-501.

Related Party and Acquisition Related Contingent Liabilities

CERC-006 Royalty Agreement with Certain Related Parties

As discussed in detail in Note 6, on February 3, 2020, the Company consummated a Merger with Aevi. Effective upon the closing of the Merger, Cerecor entered into an employment agreement with Mike Cola for him to serve as Cerecor's Chief Executive Officer and with Dr. Garry Neil for him to serve as Cerecor's Chief Medical Officer.

Prior to Cerecor entering into the Merger Agreement, in July 2019, Aevi entered into a royalty agreement with Mike Cola, ~~our~~Cerecor's current Chief Executive Officer, Joseph J. Grano, Jr., Kathleen Jane Grano, Joseph C. Grano, The Grano Children's Trust, Joseph C. Grano, trustee and LeoGroup Private Investment Access, LLC on behalf of Garry A. Neil, ~~our~~Cerecor's current Chief ~~Medical~~Scientific Officer (collectively, the "Investors") in exchange for a one-time aggregate payment of $2 million (the "Royalty Agreement"). Collectively, the Investors will be entitled to an aggregate amount equal to a low-single digit percentage of the aggregate net sales of Astellas Pharma Inc.'s second generation mTORC1/2 inhibitor, CERC-006. At any time beginning three years after the date of the first public launch of CERC-006, Cerecor may exercise, at its sole discretion, a buyout option that terminates any further obligations under the Royalty Agreement in exchange for a payment to Investors of an aggregate of 75% of the net present value of the royalty payments. A majority of the independent members of the board of directors and the audit committee of Aevi approved the Royalty Agreement.

~~Table of Contents~~

Cerecor assumed this Royalty Agreement upon closing of the Merger with Aevi and it is recorded ~~within~~as a royalty obligation within the Company's accompanying condensed consolidated balance sheet as of ~~June~~September 30, 2020. Because there is a significant related party relationship between the Company and the Investors, the Company treated its obligation to make royalty payments under the Royalty Agreement as an implicit obligation to repay the funds advanced by the Investors. As the Company makes royalty payments in accordance with the Royalty Agreement, it will reduce the liability balance. At the time that such royalty payments become probable and estimable, and if such amounts exceed the liability balance, the Company will impute interest accordingly on a prospective basis based on such estimates, which would result in a corresponding increase in the liability balance.

Table of Contents

Aevi Merger possible future milestone payments

~~As detailed in Note 6,~~A portion of the consideration for the Aevi Merger, which closed on February 3, 2020, the Company consummated its merger with Aevi, thus acquiring the rights to three early stage compounds for rare and orphan diseases (CERC-002, CERC-006 and CERC-007) and one other preclinical orphan disease compound, CERC-005. Consideration for the transaction included approximately 3.9 million shares of Cerecor common stock to Aevi stockholders, forgiveness of a $4.1 million loan that Cerecor loaned Aevi in December 2019, and certainincludes two future contingent development milestones worth up to an additional $6.5 million.

~~The contingent consideration of up to an additional $6.5 million relates to 2 future development milestones.~~ The first milestone is the enrollment of a patient in a Phase II study related to CERC-002 for use in ~~Pediatric Onset~~pediatric onset Crohn's ~~Disease,~~disease, CERC-006 or CERC-007 prior to February 3, 2022. If this milestone is met, the Company is required to make a milestone payment of $2.0 million. The second milestone is the receipt of a NDA approval for either CERC-006 or CERC-007 from the FDA on or prior to February 3, 2025. If this milestone is met, the Company is required to make a milestone payment of $4.5 million. All milestones are payable in either shares of the Company's common stock or cash, at the election of the Company.

The contingent consideration related to the development milestones will be recognized if and when such milestones are probable and can be reasonably estimated. As of the consummation of the Merger on February 3, 2020 and as of ~~June~~September 30, 2020, 0 contingent consideration related to the development milestone has been recognized. The Company will continue to monitor the development milestones at each reporting period.

Ichorion Asset Acquisition possible future milestone payments

OnIn September ~~24,~~ 2018, the Company acquired Ichorion Therapeutics, Inc. ~~(the "Ichorion Acquisition") thus~~including acquiring 3 compounds for inherited metabolic disorders known as CDGs (CERC-801, CERC-802 and CERC-803) and 1 other preclinical ~~orphan disease compound, CERC-913, for the treatment of mitochondrial DNA Depletion Syndrome.~~compound. Consideration for the transaction included ~~approximately 5.8 million~~ shares of ~~the Company’s~~Cerecor common stock ~~(adjusted for estimated working capital)~~ and ~~certain~~three future contingent development milestones for the acquired compounds worth up to an additional $15.0 million. ~~The Company recorded this transaction as an asset acquisition.~~

~~The contingent consideration of up to an additional $15.0 million relates to 3 future development milestones for the acquired compounds.~~ The first milestone is the first product being approved for marketing by the FDA on or prior to December 31, 2021. If this milestone is met, the Company is required to make a milestone payment of $6.0 million. The second milestone is the second product being approved for marketing by the FDA on or prior to December 31, 2021. If this milestone is met, the Company is required to make a milestone payment of $5.0 million. The third milestone is a protide molecule being approved by the FDA on or prior to December 31, 2023. If this milestone is met, the Company is required to make a milestone payment of $4.0 million. All milestones are payable in either shares of the Company's common stock or cash, at the election of the Company.

The contingent consideration related to the development milestones will be recognized if and when such milestones are probable and can be reasonably estimated. As of ~~June~~September 30, 2020, 0 contingent consideration related to the development milestone has been recognized. The Company will continue to monitor the development milestones at each reporting period.

14. Payroll Protection Program Loan

The CARES Act provides stimulus measures, including the ~~Payroll Protection Loan Program ("PPP"),~~PPP, to provide certain small businesses with liquidity to support their operations during the COVID-19 pandemic. Cerecor received a $0.4 million PPP Loan during the second quarter of 2020. PPP Loans have a 1% fixed annual interest rate and mature in two years, however are eligible for forgiveness under certain conditions. Cerecor used the loaned funds during the second quarter of 2020 to retain employees and maintain payroll and lease payments, as specified under the Paycheck Protection Program Rule. The Company believes it meets the criteria for forgiveness and plans to submit an application for forgiveness with its lender in the second half of 2020. Once approved by the lender, the lender will submit the forgiveness application to the Small Business Administration (the "SBA") for ultimate

~~Table of Contents~~

approval. The SBA has 90 days from receipt to approve or reject the forgiveness application. The Company incurred the related expense ~~prior to June 30,~~during the second quarter of 2020 and recognized the PPP Loan of $0.4 million as other income within the accompanying condensed consolidated statement of operations for the ~~three and six~~nine months ended ~~June~~September 30, 2020.

3229

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q and the information incorporated herein by reference contain forward-looking statements that involve a number of risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements can be identified by the use of forward-looking words such as “believes,” “expects,” “may,” “might,” “will,” “plans,” “intends,” “estimates,” “could,” “should,” “would,” “continue,” “seeks,” “aims,” “projects,” “predicts,” “pro forma,” “anticipates,” “potential” or other similar words (including their use in the negative), or by discussions of future matters such as the development of product candidates or products, technology enhancements, possible changes in legislation, and other statements that are not historical. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those below and elsewhere in this Quarterly Report on Form 10-Q, particularly in Part II – Item 1A, “Risk Factors,” as well as in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 11, 2020, and in our other filings with the SEC. Statements made herein are as of the date of the filing of this Quarterly Report on Form 10-Q with the SEC and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited financial statements and related notes that appear in Item 1 of this Quarterly Report on Form 10-Q and with our audited financial statements and related notes for the year ended December 31, 2019 appearing in our Annual Report on Form 10-K filed with the SEC on March 11, 2020.

Overview

Cerecor Inc. (the "Company" or "Cerecor") is a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare ~~pediatric~~ and orphan diseases. The Company is advancing ~~an emerging~~its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare ~~pediatric~~ and orphan diseases. The Company's ~~pediatric~~ rare disease pipeline includes CERC-801, CERC-802 and CERC-803 ("CERC-800 compounds"), which are therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation ("CDGs"). The U.S. Food and Drug Administration ("FDA") granted Rare Pediatric Disease Designation ("RPDD") and Orphan Drug Designation ("ODD") to all three CERC-800 compounds, thus potentially qualifying the Company to receive a Priority Review Voucher ("PRV") upon approval of each new drug application ("NDA"). The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes) monoclonal antibody being developed for ~~the treatment of~~ COVID-19 acute respiratory distress syndrome ~~("ARDS")~~ and ~~Pediatric-onset~~for severe pediatric-onset Crohn's ~~Disease.~~disease. CERC-006 is a dual mTOR inhibitor being developed for the treatment of complex ~~Lymphatic Malformations~~lymphatic malformations and has been granted ODD and RPDD by the FDA, thus potentially qualifying the Company to receive a fourth PRV upon approval of an NDA. CERC-007 is an anti-IL-18 monoclonal antibody being developed for the treatment of autoimmune inflammatory diseases such as ~~Adult Onset Stills Disease ("AOSD")~~adult onset Still's disease and ~~Multiple Myeloma.~~multiple myeloma.

On February 3, 2020, the Company closed on its merger (the "Merger" or the "Aevi Merger") with Aevi Genomic Medicine, Inc. ("Aevi"), in which Cerecor acquired the rights to CERC-002, CERC-006 and ~~CERC-406, to a new company formed by~~CERC-007. Additionally, certain members of Aevi's leadership joined Cerecor's management and board of directors, most notably Mike Cola, Chief Executive Officer, Dr. ~~Pedder, although it has not agreed to binding terms,~~Garry Neil, Chief Scientific Officer and ~~any such transaction might not happen until~~Dr. Sol Barer, Chairman of the ~~second half of 2020, if at all.~~Board.

Recent Developments

~~On June 11,~~In October 2020, the Company ~~closed an underwritten public offering of 15,180,000 shares of its common stock (inclusive of 1,980,000 shares that were sold pursuant~~appointed Gilla Kaplan, Ph.D., to the ~~underwriter’s full exercise~~Board of Directors. Dr. Kaplan brings with her over 30 years of academic and industry experience. The Company believes the addition of Dr. Kaplan to the Board of Directors will provide valuable insights and guidance as the Company advances its ~~option to purchase additional shares of Cerecor’s common stock)~~pipeline targeting treatments for ~~net proceeds of approximately $35.4 million. Armistice Capital, LLC ("Armistice"), whose Chief Investment Officer Steve Boyd is~~rare diseases and immune-inflammatory disorders. Additionally, the Company formed a ~~Cerecor director, participated in the offering by purchasing 2,000,000 shares of common stock, on the same terms as all other investors. Additionally, certain~~Science and Technology Committee of the ~~Company's officers participated~~Board (the "Committee"), which Dr. Kaplan will chair. Drs. Barer, Bruhn and Persson will serve as members of the Committee. The Committee's responsibilities include, but are not limited to, periodically reviewing, and advising management and the Board of Directors on, matters relating to the Company’s strategic direction and investment in ~~the offering by purchasing an aggregate of 110,000 shares of common stock, on the same terms as all other investors.~~

~~Research~~research, development and ~~Development Update~~technology.

3330

Table of Contents

Research and Development Updates

In ~~July~~August 2020, the Company announced the publication of a peer-reviewed paper demonstrating significantly elevated free LIGHT levels in the serum of hospitalized patients with severe COVID-19 infection. The publication, titled Levels of the TNF related cytokine, LIGHT, increased in hospitalized COVID-19 patients with Cytokine Release Syndrome and ARDS in the Journal mSphere by David S. Perlin et al, highlights the potential role of the inflammatory cytokine, LIGHT in the development of COVID-19 ARDS. We believe that the ~~first patient was enrolled~~publication supports our clinical program evaluating CERC-002 as a potential treatment for patients with severe COVID-19 ARDS. Cerecor is currently enrolling patients in aits proof-of-concept trial evaluating the safety and efficacy of ~~the anti-LIGHT monoclonal antibody,~~ CERC-002 in patients with COVID-19 cytokine storm-induced ARDS. The ~~proof-of-concept, randomized, multicenter, double-blind, placebo-controlled trial will enroll approximately 82 subjects hospitalized with COVID-19 ARDS. The~~ primary objective of the ~~study~~trial is to demonstrate that treatment with CERC-002 results in fewer instances of respiratory failure and death versus the standard of care. Top-line data is expected in the fourth quarter of 2020. Prior to enrollment, in May 2020, the Company received clearance from the FDA to proceed with the proof-of-concept trial. The scientific rationale for the proof-of-concept trial is supported by recent biomarker data demonstrating elevated levels of LIGHT in patients hospitalized with COVID-19 cytokine storm-induced ARDS.

In May 2020, Cerecor entered into an Amended and Restated Clinical Development and Option Agreement (the "New CDOA") with Kyowa Kirin Co., Ltd., formerly known as Kyowa Hakko Kirin Co., Ltd ("KKC") relating to the development and potential commercialization of CERC-002 in the treatment of COVID-19 ARDS. The New CDOA grants Cerecor an additional option to obtain exclusive rights for the development, manufacture and commercialization of CERC-002 in the treatment, prevention, and diagnosis of acute lung injury ("ALI") and ARDS, for an initial license fee in the low single-digit millions of dollars upon exercise of the option. The New CDOA includes additional terms, such as certain regulatory milestone payments and profit sharing specifically related to CERC-002 in the ARDS/ALI Field.

During the second quarter of 2020, the Company concluded its CDG FIRST trial, which was a retrospective trial evaluating the use of monosaccharide replacement therapy in PGMI-CDG, MPI-CDG and LADII-CDG. The Company plans to use data from this trial to inform future trial design and endpoints for forthcoming pivotal trials for the CERC-800s.

During the first quarter of 2020, the Company paused its Phase 1b open-label, multi-center, dose-escalation proof-of-concept study for CERC-002 for the treatment of Pediatric-onset Crohn's Disease due to a moratorium placed on endoscopy as a result of COVID-19. The Company resumed this trial in July 2020.

In the third quarter of 2020, the FDA granted ODD and RPDD to CERC-006. There are numerous benefits associated with receipt of ODD, which include seven-year marketing exclusivity (upon FDA approval) in the United States, exemption of FDA application fees and tax credits for qualified clinical trials. RPDD provides potential eligibility for receipt of a PRV upon approval of an NDA.

The following chart summarizes key information about our emerging clinical-stage rare disease pipeline and anticipated research & development milestones:

~~Table of Contents~~

Our Strategy

Our strategy for increasing ~~shareholder~~stockholder value includes:

•Advancing our pipeline of compounds through development and to regulatory approval;

•Acquiring or licensing rights to targeted, complementary differentiated preclinical and clinical stage assets;

•Developing the go-to-market strategy to quickly and effectively market, launch, and distribute each of our assets that receive ~~marketing~~regulatory approval;

•Opportunistically out-licensing rights to indications or geographies; and

•Opportunistically out-licensing rights to, or sale of, non-core assets.

Results of Operations

Table of Contents

During the fourth quarter of 2019, the Company sold to Aytu BioScience its rights, titles and interest in, assets relating to its Pediatric Portfolio, namely Aciphex® Sprinkle™, Cefaclor for Oral Suspension, Karbinal™ ER, Flexichamber™ , Poly-Vi-Flor® and Tri-Vi-Flor™ (the "Pediatric Portfolio"), as well as the corresponding commercial infrastructure consisting of the right to offer employment to Cerecor’s sales force and the assignment of supporting commercial contracts, retaining as our only commercial product, Millipred, an oral prednisolone indicated across a wide variety of inflammatory conditions (the "Aytu Divestiture"). As a result, the Pediatric Portfolio met all conditions required in order to be classified as discontinued operations. Accordingly, unless otherwise noted, the following section focuses on results of operations from continuing operations only for all periods discussed.

Comparison of the Three Months Ended ~~June~~September 30, 2020 and 2019

Product Revenue, net

Net product revenue was $1.1 million for the three months ended September 30, 2020, as compared to $2.1 million for the three months ended September 30, 2019. During the second quarter of 2019, the Company entered into a settlement agreement related to the Ulesfia product in which Cerecor gave up its rights to sell the product, except for the limited amount of inventory on hand (which was depleted in the fourth quarter of 2019). Therefore, net product revenue for the three months ended September 30, 2019 include sales of the Ulesfia and Millipred products while sales for the same period in 2020 include sales of Millipred only, which was the reason for substantially all of the period-to-period decrease in net product revenue.

During the third quarter of 2020, the Company received notice from Teva Pharmaceutical Industries Ltd. ("Teva") of its termination of the License and Supply Agreement for the Millipred product, effective April 1, 2021, however the agreement allows for the Company to sell the existing inventory on hand at April 1, 2021 for a period of six months after such date. The Company is currently in negotiations with Teva to extend the term of the License and Supply Agreement, however there can be no guarantee that any such extension will be granted. Dr. Sol Barer is the Chairman of Cerecor's Board of Directors and he also serves as the Chairman of Teva's Board. Finally, the Company continues to explore strategic alternatives for this product.

License and Other Revenue

During the third quarter of 2019, the Company assigned and transferred its rights, title, interest, and obligations with respect to CERC-611 to ES Therapeutics in exchange for initial gross proceeds of $0.1 million, which was recognized as license and other revenue for the three months ended September 30, 2019. The Company is also eligible for potential milestone payments upon achievement of certain targets of cumulative net sales of the licensed product. There was no license and other revenue for the three months ended September 30, 2020.

Cost of Product Sales

Cost of product sales was $0.1 million for the three months ended September 30, 2020, which was substantially the same as the cost of product sales for the three months ended September 30, 2019.

Research and Development Expenses

The following table summarizes our research and development expenses for the three months ended September 30, 2020 and 2019:


	Three Months Ended September 30,
	2020		2019

	(in thousands)
Preclinical expenses	$	1,105	$	182
Clinical expenses	2,768		654
CMC expenses	3,200		1,382
Internal expenses not allocated to programs:
Salaries, benefits and related costs	1,377		581
Stock-based compensation expense	384		176
Other	38		(1,232)
	$	8,872	$	1,743

Table of Contents

~~Net product revenue was $1.3~~

Research and development expenses increased $7.1 million for the three months ended ~~June 30, 2020, which was relatively consistent with the net product revenue for the three months ended June 30, 2019 of $1.4 million.~~

~~Cost of Product Sales~~

Cost of product sales was $0.1 million for the three months ended June 30, 2020, as compared to $(1.5) million for the three months ended June 30, 2019. The $1.5 million reversal of expense for the three months ended June 30, 2019 was driven by a settlement agreement the Company entered into related to the Ulesfia product during the second quarter of 2019, which fully released the Company of its minimum purchase obligations and minimum royalty provisions related to the Ulesfia product.

~~Research and Development Expenses~~

~~The following table summarizes our research and development expenses for the three months ended June 30, 2020 and 2019:~~

Three Months Ended June 30,
2020 2019
(in thousands)
Preclinical expenses $ 1,572 $ 667
Clinical expenses 1,347 1,691
CMC expenses 1,204 755
Internal expenses not allocated to programs:
Salaries, benefits and related costs 1,201 474
Stock-based compensation expense 391 121
Other 202 5
$ 5,917 $ 3,713

~~Research and development expenses increased $2.2 million for the three months ended June~~September 30, 2020 compared to the same period in 2019. The overall increase was driven by an increase in research and development activities ~~in the current year~~during 2020 as the Company expanded and advanced its pipeline assets, ~~as a result of~~including the rights to the additional assets acquired in the Aevi ~~Merger and continued to develop its existing pipeline assets during the quarter.~~Merger.

~~Preclinical~~Clinical expenses increased ~~$0.9~~$2.1 million primarily due to ~~additional spending related~~costs incurred for the CERC-002 proof-of-concept trial in patients with COVID-19 induced ARDS, which began in July 2020. Additionally, clinical expenses were higher for the CERC-800 programs as we continued to advance the ~~Aevi Merger.~~programs. Chemistry, Manufacturing, and Controls ("CMC") expenses increased ~~$0.4~~$1.8 million ~~for the three months ended June 30, 2020 compared to the same period in 2019~~ due to additional spending on manufacturing to support clinical development ~~as a result~~ of the ~~Company acquiring~~expanded pipeline. Preclinical expenses increased $0.9 million primarily due to the development of a more robust pipeline given the rights acquired to develop additional assets ~~from~~in the Aevi Merger. These increases were partially offset by a $0.3 million decrease in clinical expenses driven by minimal spend on clinical development of CERC-301 as the Company began exploring strategic alternatives for the asset during 2019.

Salaries, benefits and related costs increased by ~~$0.7~~$0.8 million ~~compared to the same period in 2019~~ mainly due to an increase in headcount as a result of the Aevi Merger and salary-related costs to grow our research and development activities as we continue to invest in our expanded pipeline. ~~Stock-based compensation increased~~

The $1.3 million increase to other expenses was primarily driven by ~~$0.3~~the reversal of $1.3 million ~~mainly due to an increase in stock option grants~~of research and development expense for the three months ended September 30, 2019, which was reversed as a result of the ~~increased headcount~~Company's assignment of the CERC-611 license agreement to ES Therapeutics in the third quarter of 2019. As part of the assignment, the Company was released of a contingent payment liability of $1.3 million due to Eli Lilly Company ("Lilly") upon the first subject dosage of CERC-611 in a multiple ascending dose study, which was previously recorded as a license obligation on the balance sheet. The decrease of the license obligation to $0 as of September 30, 2019 resulted in an offset of research and development expense for the three months ended September 30, 2019. There was no such reversal in the three months ended September 30, 2020, resulting in an overall increase as compared to the same prior year period.

We expect research and development expenses to continue to outpace historic periods prior to the Aevi Merger, ~~and~~as the ~~Company's annual stock option grant in April 2020.~~Company advances its expanded pipeline.

General and Administrative Expenses

The following table summarizes our general and administrative expenses for the three months ended ~~June~~September 30, 2020 and 2019:


	Three Months Ended September 30,
	2020		2019

	(in thousands)
Salaries, benefits and related costs	$	957	$	852
Legal, consulting and other professional expenses	2,389		1,197
Stock-based compensation expense	972		474
Other	255		115
	$	4,573	$	2,638

General and administrative expenses were $4.6 million for the three months ended September 30, 2020, which represents a $1.9 million increase from the prior year period. The overall increase was largely driven by a $1.2 million increase in legal, consulting and other professional expenses. The increase in legal, consulting and other professional expenses was largely related to the settlement agreement entered into during the quarter with the former owners of TRx Pharmaceuticals, LLC ("TRx"), which Cerecor acquired in 2017 (and partially divested in 2019 as part of the Aytu Divestiture). As part of the settlement, Cerecor made a $0.9 million payment to the former TRx owners to settle all known disputes and claims between all parties, which was recognized within general and administrative expenses (refer to Note 13 to our unaudited condensed consolidated financial statements for more information).

Stock-based compensation expense increased $0.5 million as a result of $0.3 million of expense recognized related to equity awards granted to new executive leadership and board members appointed in 2020.

Sales and Marketing Expenses

The following table summarizes our sales and marketing expenses for the three months ended September 30, 2020 and 2019:

3633

Table of Contents

Three Months Ended June 30,
2020 2019
(in thousands)
Salaries, benefits and related costs $ 1,756 $ 1,226
Legal, consulting and other professional expenses 1,804 774
Stock-based compensation expense 2,286 196
Other 255 145
$ 6,101 $ 2,341

General and administrative expenses were $6.1 million for the three months ended June 30, 2020, which represents a $3.8 million increase from the prior period. The increase was largely driven by a $2.1 million increase in stock-based compensation expense as a result of $0.8 million of expense recognized related to an equity award granted to the Company's Chairman of the Board during the second quarter of 2020, expense recognized related to the modifications of certain former executives' and board members' equity awards due to leadership changes during the quarter and an increase in stock option grants as a result of the Company's annual grant in April 2020 and increased headcount as a result of the Aevi Merger. Additionally, legal, consulting and other professional expenses increased by $1.0 million due to increased patent costs driven by the additional assets acquired as part of Aevi Merger, increased recruiting costs, and increased legal fees related to leadership changes and contract reviews performed. Salaries, benefits and related costs increased $0.5 million mainly due to a severance accrual related to the resignation of an executive during the second quarter of 2020.

~~Sales and Marketing Expenses~~

~~The following table summarizes our sales and marketing expenses for the three months ended June 30, 2020 and 2019:~~


		Three Months Ended June 30,							Three Months Ended September 30,
		2020		2019			2020		2019

		(in thousands)							(in thousands)
Salaries, benefits and related costs	Salaries, benefits and related costs	$	183	$	121	Salaries, benefits and related costs	$	214	$	127
Stock-based compensation expense	Stock-based compensation expense	87		57		Stock-based compensation expense	92		58
Advertising and marketing expense	Advertising and marketing expense	366		148		Advertising and marketing expense	141		25
Other	Other	17		—		Other	15		5
		$	653	$	326		$	462	$	215

Amortization Expense

The following table summarizes our amortization expense for the three months ended ~~June~~September 30, 2020 and 2019:

Three Months Ended June 30,
2020 2019
(in thousands)
Amortization of intangible assets $ 404 $ 335


	Three Months Ended September 30,
	2020		2019

	(in thousands)
Amortization of intangible assets	$	404	$	335

Amortization expense ~~of the continuing operations~~ relates primarily to the ~~amortization of the Company's acquired Millipred product marketing rights and~~ amortization of the assembled workforce acquired as part of the Aevi ~~Merger.~~Merger in the first quarter of 2020 and the amortization of the Millipred product marketing rights acquired as part of the acquisition of TRx in 2017. As a result of the asset acquisition accounting treatment of the Aevi Merger, ~~in the first quarter of 2020,~~ the Company recorded an assembled workforce intangible asset of $0.7 million, which was assigned a two-year useful life. Therefore, the $0.1 million increase to amortization expense ~~for the three months ended June 30, 2020 as compared to the prior period~~ was primarily driven by the amortization ~~expense~~ of the assembled workforce acquired ~~as part of~~in the Aevi Merger.

~~Table of Contents~~

~~Other (Expense) Income, Net~~

~~The following table summarizes our other income (expense), net for the three months ended June 30, 2020 and 2019:~~

Three Months Ended June 30,
2020 2019
(in thousands)
Change in fair value of Investment in Aytu $ (1,872) $ —
Change in fair value of warrant liability and unit purchase option liability 3 19
Other income (expense), net 396 —
Interest income, net 9 38
$ (1,464) $ 57

Other expense, net increased $1.5 million for the three months ended June 30, 2020 as compared to the prior period. Other expense, net is mainly comprised of a $1.9 million loss on change in the fair value of the Company's Investment in Aytu. As consideration of the Aytu Divestiture in November 2019, the Company received 9,805,845 shares of Aytu Series G Preferred Stock, which was remeasured at the current fair value each reporting period with the change in fair value recorded to other (expense) income, net in the accompanying statements of operations. In April 2020, the Company converted its shares of Aytu Preferred Stock into approximately 9.8 million shares of common and sold that common stock for net proceeds of approximately $12.8 million. Therefore, the Company's Investment in Aytu was $0 as of June 30, 2020, which represented a $1.9 million loss on change in the fair value for the three months ended June 30, 2020. The loss was driven by a decrease in Aytu's stock price from March 31, 2020 to the dates the Company sold its shares of Aytu common stock in mid-April 2020.

The increase in other expense, net was partially offset by other income recognized on the $0.4 million Payroll Protection Program ("PPP") Loan received by the Company during the second quarter of 2020. The PPP Loan Program is part of the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") which serves to provide certain small businesses with liquidity to support their operations during the COVID-19 pandemic. PPP Loans are eligible for forgiveness under certain conditions. The Company believes it meets the criteria for forgiveness and plans to submit an application for forgiveness during the third quarter of 2020. Therefore, the Company recognized $0.4 million as other income for the three months ended June 30, 2020.

Income Tax ~~(Benefit)~~ Expense

The following table summarizes our income tax ~~(benefit)~~ expense for the three months ended ~~June~~September 30, 2020 and 2019:

Three Months Ended June 30,
2020 2019
(in thousands)
Income tax (benefit) expense $ (454) $ 53


	Three Months Ended September 30,
	2020		2019

	(in thousands)
Income tax (benefit) expense	$	3	$	122

The Company recognized an ~~income tax benefit of $0.5 million for the three months ended June 30, 2020 and~~ income tax expense of $0.1 million for the three months ended ~~June~~September 30, ~~2019. The 2020 tax benefit recognized was~~2019 as a result of ~~a current year tax law change~~estimated cash taxes and ~~the ability of the Company to now carry back certain losses~~deferred taxes related to the ~~CARES Act and related state~~amortization of tax ~~provisions. The expense recognized for the three months ended June 30, 2019 was a result of~~deductible goodwill, as well as interest on an unpaid tax ~~liability related to the 2017 tax year and state taxes.~~liability.

Comparison of the ~~Six~~Nine Months Ended ~~June~~September 30, 2020 and 2019

Product Revenue, net

Net product revenue was ~~$4.1~~$5.2 million for the ~~six~~nine months ended ~~June 30, 2020, which was relatively consistent with the net product revenue for the six months ended June 30, 2019.~~

~~Cost of Product Sales~~

~~Cost of product sales were $0.1 million for the six months ended June~~September 30, 2020, as compared to ~~$(0.7)~~$6.1 million for the ~~six~~nine months ended ~~June~~September 30, 2019. During the second quarter of 2019, the Company entered into a settlement agreement related to the Ulesfia product in which Cerecor gave up its rights to sell the product, except for the limited amount of inventory on hand (which was depleted in the fourth quarter of 2019). Therefore, net product revenue for the nine months ended September 30, 2019 includes sales of the Ulesfia and Millipred products while sales for the same period in 2020 include sales of Millipred only, which was the reason for substantially all of the period-to-period decrease in net product revenue.

3834

Table of Contents

During the third quarter of 2020, the Company received notice from Teva of its termination of the License and Supply Agreement for the Millipred product, effective April 1, 2021, however the agreement allows for the Company to sell the existing inventory on hand at April 1, 2021 for a period of six months after such date. The Company is currently in negotiations with Teva to extend the term of the License and Supply Agreement, however there can be no guarantee that any such extension will be granted. Dr. Sol Barer is the Chairman of Cerecor's Board of Directors and he also serves as the Chairman of Teva's Board of Directors. Finally, the Company continues to explore strategic alternatives for this product.

License and Other Revenue

During the third quarter of 2019, the Company assigned and transferred its rights, title, interest, and obligations with respect to CERC-611 to ES Therapeutics in exchange for initial gross proceeds of $0.1 million, which was recognized as license and other revenue for the nine months ended September 30, 2019. The Company is also eligible for potential milestone payments upon achievement of certain targets of cumulative net sales of the licensed product. There was no license and other revenue for the nine months ended September 30, 2020.

Cost of Product Sales

Cost of product sales were $0.2 million for the nine months ended September 30, 2020, as compared to $(0.6) million for the nine months ended September 30, 2019. During the second quarter of 2019, the Company entered into a settlement agreement related to the Ulesfia product, which fully released the Company of its minimum purchase obligations and minimum royalty provisions related to the Ulesfia product resulting in a reversal of expense of approximately $1.6 million. The reversal of expense was partially offset by minimum royalty obligations related to the Ulesfia product recognized in the first quarter of 2019 prior to entering into the settlement agreement.

Research and Development Expenses

The following table summarizes our research and development expenses for the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019:


		Six Months Ended June 30,							Nine Months Ended September 30,
		2020		2019			2020		2019

		(in thousands)							(in thousands)
Preclinical expenses	Preclinical expenses	$	2,818	$	1,547	Preclinical expenses	$	4,019	$	1,842
Clinical expenses	Clinical expenses	1,944		3,280		Clinical expenses	4,663		3,800
CMC expenses	CMC expenses	2,370		1,190		CMC expenses	5,721		2,595
Internal expenses not allocated to programs:	Internal expenses not allocated to programs:					Internal expenses not allocated to programs:
Salaries, benefits and related costs	Salaries, benefits and related costs	2,514		908		Salaries, benefits and related costs	3,891		1,489
Stock-based compensation expense	Stock-based compensation expense	772		178		Stock-based compensation expense	1,156		354
Other	Other	267		11		Other	106		(1,223)
		$	10,685	$	7,114		$	19,556	$	8,857

Research and development expenses increased ~~$3.6~~$10.7 million for the ~~six~~nine months ended ~~June~~September 30, 2020 compared to the same period in 2019. The overall increase was driven by an increase in research and development activities in ~~the current year~~2020 as the Company expanded and advanced its pipeline assets, ~~as a result~~including the rights to the additional assets acquired in the Aevi Merger.

CMC expenses increased $3.1 million due to additional spending on manufacturing to support development of the ~~Aevi Merger and continued~~Company's expanded pipeline. Similarly, preclinical expenses increased $2.2 million primarily due to the development of a more robust pipeline given the rights acquired to develop ~~its existing~~additional assets in the Aevi Merger. Clinical expenses increased $0.9 million primarily due to costs incurred for the CERC-002 proof-of-concept trial in patients with COVID-19 ARDS, which began in July 2020, and additional spending related to development of the other core pipeline assets, ~~during~~partially offset by decreased spend on the ~~quarter.~~non-core neurology assets.

Salaries, benefits and related costs increased by ~~$1.6~~$2.4 million ~~compared to the same period in 2019~~ mainly due to an increase in headcount as a result of the Aevi Merger and salary-related costs to grow our research and development activities as we continue to invest in our expanded pipeline. ~~Additionally,~~Stock-based compensation increased by $0.8 million mainly due to an increase in stock option grants as a result of the ~~Company recognized $0.3~~increased headcount.

Table of Contents

The $1.3 million increase to other expenses was primarily driven by the reversal of ~~severance within salaries, benefits and related costs for the six months ended June 30, 2020 related to a separation agreement entered into with a~~$1.3 million of research and development ~~executive during~~expense for the nine months ended September 30, 2019, which was reversed as a result of the Company's assignment of the CERC-611 license agreement to ES Therapeutics in the third quarter of 2019. As part of the assignment, the Company was released of a contingent payment liability of $1.3 million to Lilly upon the first ~~quarter~~subject dosage of ~~2020.~~CERC-611 in a multiple ascending dose study, which was previously recorded as a license obligation on the balance sheet. The decrease of the license obligation to $0 as of September 30, 2019 resulted in an offset of research and development expense for the nine months ended September 30, 2019. There was no ~~severance for~~such reversal in the ~~six~~nine months ended ~~June~~September 30, ~~2019.~~

Preclinical expenses increased $1.3 million primarily due to additional spending related to the Aevi Merger. Similarly, Chemistry, Manufacturing, and Controls ("CMC") expenses increased $1.2 million for the six months ended June 30, 2020, thus resulting in an overall increase as compared to the same ~~period in 2019 due~~prior year period.

We expect research and development expenses to ~~additional spending on manufacturing~~continue to ~~support development of~~outpace historic periods prior to the Company's expanded pipeline. These increases were partially offset by a $1.3 million decrease in clinical expenses driven by minimal spend on clinical development of the Company's non-core neurology assetsAevi Merger, as the Company ~~began exploring strategic alternatives for the asset during 2019.~~advances its expanded pipeline.

Acquired In-Process Research and Development Expenses

On February 3, 2020, the Company consummated its merger with Aevi, which was recorded as an asset acquisition. As a result, the Company acquired $25.5 million of in-process research and development ("IPR&D") ~~for two clinical stage pipeline assets for rare and orphan diseases (CERC-006 and CERC-007)~~. The fair value of the IPR&D was immediately recognized as acquired in-process research and development expense as the IPR&D asset has no other alternate use due to the stage of development. There was no acquired in-process research and development expense for the ~~six~~nine months ended ~~June~~September 30, 2019.

General and Administrative Expenses

The following table summarizes our general and administrative expenses for the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019:

~~Table of Contents~~


		Six Months Ended June 30,							Nine Months Ended September 30,
		2020		2019			2020		2019

		(in thousands)							(in thousands)
Salaries, benefits and related costs	Salaries, benefits and related costs	$	2,768	$	2,456	Salaries, benefits and related costs	$	3,725	$	3,308
Legal, consulting and other professional expenses	Legal, consulting and other professional expenses	2,588		1,661		Legal, consulting and other professional expenses	4,977		2,858
Stock-based compensation expense	Stock-based compensation expense	2,992		665		Stock-based compensation expense	3,963		1,139
Other	Other	429		235		Other	685		349
		$	8,777	$	5,017		$	13,350	$	7,654

General and administrative expenses increased ~~$3.8~~$5.7 million for the ~~six~~nine months ended ~~June~~September 30, 2020 compared to the same period in 2019. The increase was largely driven by a ~~$2.3~~$2.8 million increase to stock-based compensation expense as a result of ~~$0.8 million of expense recognized related to an~~ equity ~~award~~awards granted to ~~the Company's Chairman of the Board during the second quarter of 2020, expense recognized related to the modifications of certain former executives'~~newly appointed executive leadership and board ~~members' equity awards due to leadership changes during the quarter and an~~members.

The increase in ~~stock option grants as a result of the Company's annual grant in April 2020 and increased headcount as a result of the Aevi Merger. Legal,~~legal, consulting and other professional expenses ~~increased~~ by $2.1 million was largely related to a $0.9 million ~~due~~expense recognized related to ~~increased patent costs driven by~~a payment made pursuant to a settlement agreement entered into during the ~~additional assets acquired as part~~third quarter with the former owners of ~~the Aevi Merger,~~TRx; refer to Note 13 to our unaudited condensed consolidated financial statements for more information. The remainder of this increase was attributable to a variety of factors including increased recruiting costs incurred to grow research and ~~increased legal fees related~~development headcount to ~~leadership changes and contract reviews performed. Additionally, salaries, benefits and related costs increased $0.3 million mainly due to a severance accrual related to~~support the ~~resignation of an executive during the second quarter of 2020.~~expanded pipeline development.

Sales and Marketing Expenses

The following table summarizes our sales and marketing expenses for the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019:

Six Months Ended June 30,
2020 2019
(in thousands)
Salaries, benefits and related costs $ 317 $ 306
Stock-based compensation expense 142 78
Advertising and marketing expense 848 338
Other 23 —
$ 1,330 $ 722

Table of Contents


	Nine Months Ended September 30,
	2020		2019

	(in thousands)
Salaries, benefits and related costs	$	530	$	433
Stock-based compensation expense	234		135
Advertising and marketing expense	989		362
Other	39		6
	$	1,792	$	936

Sales and marketing expenses of continuing operations consist of expenses related to advertising and marketing initiatives to support the go-to-market strategy of our pipeline assets and the respective salaries and stock-based compensation to support such initiatives. The overall ~~$0.6~~$0.9 million increase ~~for the six months ended June 30, 2020 as compared to the same period in 2019~~ was ~~primarily~~ driven by a ~~$0.5~~$0.6 million increase in advertising and marketing expense related to market research, a $0.1 million increase in salaries, benefits and related costs driven by increased headcount to support such initiatives and a $0.1 million increase in stock-based compensation expense driven by an increase in stock option grants as a result of the Company's annual grant in April 2020 and increased headcount as a result of the Aevi ~~Merger which closed during the first quarter of 2020.~~Merger.

Amortization Expense

The following table summarizes our amortization expense for the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019:

Six Months Ended June 30,
2020 2019
(in thousands)
Amortization of intangible assets 834 669


	Nine Months Ended September 30,
	2020	2019

	(in thousands)
Amortization of intangible assets	1,238	1,004

Amortization expense ~~of the continuing operations~~ relates to the ~~amortization of the Company's acquired Millipred product marketing rights and~~ amortization of the assembled workforces acquired as part of the Aevi Merger in the first quarter of 2020 and the Ichorion Acquisition in September 2018 and ~~Aevi Merger.~~the amortization of the Millipred product marketing rights acquired as part of the acquisition of TRx in 2017. As a result of the asset acquisition accounting treatment of the Aevi Merger, ~~in the first quarter of 2020,~~ the Company recorded an assembled workforce intangible asset of $0.7 million, which was assigned a two-year useful life. Therefore, the $0.2 million increase to amortization expense was primarily driven by the amortization of the assembled workforce acquired as part of the Aevi Merger.

Change in fair value of contingent consideration

The following table summarizes our change in fair value of contingent consideration for the nine months ended September 30, 2020 and 2019:


	Nine Months Ended September 30,
	2020	2019

	(in thousands)
Change in fair value of contingent consideration	—	(1,256)

The Company recognized a gain on the change in fair value of contingent consideration of $1.3 million for the nine months ended September 30, 2019. The contingent consideration was related to the potential for future payment of consideration that was contingent upon the achievement of operation and commercial milestones related to the Ulesfia product, which was acquired as part of the Company's acquisition of TRx in 2017.

During the second quarter of 2019, the Company entered into a settlement agreement related to the Ulesfia product, which released the Company from the potential contingent payments related to the TRx acquisition, reducing the fair value down to $0. This represented a gain on the change of fair value of contingent consideration of $1.3 million for the nine months ended September 30, 2019. As the Company was released from the contingent payment in 2019, there is no change in fair value of contingent consideration for the nine months ended September 30, 2020.

Other Income, Net

4037

Table of Contents

million increase to amortization expense for the six months ended June, 2020 as compared to the prior period was primarily driven by the amortization expense of the assembled workforce acquired as part of the Aevi Merger.

~~Other Income, Net~~

The following table summarizes our other income, ~~(expense),~~ net for the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019:

Six Months Ended June 30,
2020 2019
(in thousands)
Change in fair value of Investment in Aytu 5,208 —
Change in fair value of warrant liability and unit purchase option liability 14 (29)
Other income (expense), net 396 (9)
Interest income, net 19 69
$ 5,637 $ 31


	Nine Months Ended September 30,
	2020		2019

	(in thousands)
Change in fair value of Investment in Aytu	5,208		—
Other income, net	447		83
	$	5,655	$	83

Other income, net increased $5.6 million for the ~~six~~nine months ended ~~June~~September 30, 2020 as compared to the prior year period. Other income, net is mainly comprised of a $5.2 million gain on change in the fair value of the Company's Investment in Aytu. As consideration of the Aytu Divestiture in November 2019, the Company received 9,805,845 shares of Aytu Series G Preferred Stock, which was remeasured at the current fair value each reporting ~~period with the change in fair value recorded to other (expense) income, net in the accompanying statements of operations.~~period. In April 2020, the Company converted its shares of Aytu Preferred Stock into ~~approximately~~ 9.8 million shares of common and sold that common stock for net proceeds of approximately $12.8 million, thus representing a realized gain of $5.2 million from December 31, ~~2019, which was recognized in the change in fair value of Investment in Aytu within the accompanying condensed consolidated statement of operations.~~2019. The gain was primarily driven by a significant increase in Aytu's stock price from December 31, 2019 to the dates the Company sold its shares of Aytu common stock in mid-April 2020.

Additionally, the Company recognized $0.4 million of other income for the ~~six~~nine months ended ~~June~~September 30, 2020 related to the ~~PPP~~Payroll Protection Program ("PPP") Loan received during the second quarter of 2020. The PPP Loan Program is part of the CARES Act, which serves to provide certain small businesses with liquidity to support their operations during the COVID-19 pandemic. PPP Loans are eligible for forgiveness under certain conditions. The Company believes it meets the criteria for loan forgiveness and ~~submitted an application for forgiveness in July 2020. Therefore, the Company~~therefore recognized $0.4 million as other income for the ~~three~~nine months ended ~~June~~September 30, 2020. Both transactions were unique to 2020, thus causing the increase as compared to the prior year period.

Income Tax (Benefit) Expense

The following table summarizes our income tax (benefit) expense for the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019:

Six Months Ended June 30,
2020 2019
(in thousands)
Income tax (benefit) expense (2,611) 184


	Nine Months Ended September 30,
	2020	2019

	(in thousands)
Income tax (benefit) expense	(2,608)	306

The Company recognized an income tax benefit of $2.6 million for the ~~six~~nine months ended ~~June~~September 30, 2020 and income tax expense of ~~$0.2~~$0.3 million for the ~~six~~nine months ended ~~June~~September 30, 2019. The tax benefit recognized for the ~~six~~nine months ended ~~June~~September 30, 2020 was a result of a current year tax law change and the ability of the Company to now carry back certain losses related to the CARES Act and related state tax provisions. Such benefit was recognized in the first and second quarters. The expense recognized for the ~~six~~nine months ended ~~June~~September 30, 2019 was a result of estimated cash taxes and deferred taxes related to the amortization of tax deductible goodwill, as well as interest on an unpaid tax ~~liability related to the 2017 tax year and state taxes~~liability.

Liquidity and Capital Resources

~~Table of Contents~~

approximately $5.1 million. ~~See Note 9 for more information regarding these financings.~~ Additionally, in April 2020, the Company converted its shares of Aytu preferred stock that were acquired in the fourth quarter of 2019 ~~and subsequently sold that~~to Aytu common stock, which ~~generated~~it subsequently sold for net proceeds of approximately $12.8 million. As of ~~June~~September 30, 2020, Cerecor had ~~$45.4~~$33.4 million in cash and cash equivalents.

Table of Contents

Over the long term, the Company's ultimate ability to achieve and maintain profitability will ~~be dependent~~depend on, among other things, the development, regulatory approval, and commercialization of its pipeline assets, and the potential receipt and sale of any PRVs it receives, in order to support its cost structure and pipeline asset development.

Uses of Liquidity

The Company uses cash to fund research and development expenses related to its core asset pipeline, business development and costs associated with its organizational infrastructure.

Cash Flows

The following table summarizes our cash flows for the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019:


		Six Months Ended June 30,							Nine Months Ended September 30,
		2020		2019			2020		2019

		(in thousands)							(in thousands)
Net cash provided by (used in):	Net cash provided by (used in):					Net cash provided by (used in):
Operating activities	Operating activities	$	(14,294)	$	(9,839)	Operating activities	$	(26,164)	$	(17,454)
Investing activities	Investing activities	11,586		(257)		Investing activities	11,523		(262)
Financing activities	Financing activities	44,583		8,914		Financing activities	44,584		12,424
Net increase (decrease) in cash and cash equivalents	Net increase (decrease) in cash and cash equivalents	$	41,875	$	(1,182)	Net increase (decrease) in cash and cash equivalents	$	29,943	$	(5,292)

Net cash used in operating activities

~~Table of Contents~~

Net cash used in operating activities was ~~$14.3~~$26.2 million for the ~~six~~nine months ended ~~June~~September 30, 2020, consisting primarily of a net loss of ~~$34.4~~$47.9 million, which was driven by increased research and development activities as the Company continued to fund its pipeline of development assets and non-cash adjustments to reconcile net loss to net cash used in operating activities including a $5.2 million realized gain related to the change in fair value of the Investment in Aytu and a $1.8 million gain related to the change in value of the Guarantee associated with the Aytu Divestiture. This decrease was offset by the following non-cash adjustments: non-cash acquired IPR&D expense of $25.5 million and non-cash stock-based compensation of ~~$3.9~~$5.4 million. Additionally, changes in net ~~assets,~~liabilities increased by ~~a net $2.8~~$3.9 million, mainly driven by a ~~$1.9~~$4.2 million decrease in other receivables, a $0.7 million decrease in prepaid expenses and a $1.8 million increase in ~~other receivables. Other receivables increased mainly due to~~accrued expenses, partially offset by a ~~$2.2~~$0.5 million ~~income tax receivable.~~decrease in accounts payable.

Table of Contents

Net cash used in operating activities was ~~$9.8~~$17.5 million for the ~~six~~nine months ended ~~June~~September 30, 2019 and consisted primarily of a net loss of ~~$13.7~~$17.7 million, which was driven by increased research and development activities as the Company continued to fund its pipeline of development assets and also by increased sales and marketing expenses incurred to support commercial sales activities. The net loss was partially offset by non-cash depreciation and amortization of ~~$2.2~~$3.3 million, non-cash impairment of intangible assets of $1.4 million related to the impairment of an intangible asset (of discontinued operations), non-cash stock-based compensation expense of ~~$1.1~~$1.9 million, and changes in working capital, primarily, a decrease in accrued expenses and other liabilities of ~~$6.3~~$6.6 million offset by a decrease in other receivables of $5.3 million.

~~Net~~The Company's net cash used in operating activities includes offsets from the collection of sales from Millipred. During the third quarter of 2020, the Company received notice from Teva of its termination of the License and Supply Agreement for the Millipred product, effective April 1, 2021, however the agreement allows for the Company to sell the existing inventory on hand at April 1, 2021 for a period of six months after such date. The Company is currently in negotiations with Teva to extend the term of the License and Supply Agreement, however there can be no guarantee that any such extension will be granted. Dr. Sol Barer is the Chairman of Cerecor's Board of Directors and he also serves as the Chairman of Teva's Board. Finally, the Company continues to explore strategic alternatives for this product.

Net cash provided by (used in) investing activities

Net cash provided by investing activities was ~~$11.6~~$11.5 million for the ~~six~~nine months ended ~~June~~September 30, 2020 and consisted primarily of net proceeds of $12.8 million from the sale of the Aytu common stock during the second quarter of 2020 underlying the Company's previous Investment in Aytu, slightly offset by transaction costs incurred as part of the Aevi Merger.

Net cash used in investing activities was $0.3 million for the ~~six~~nine months ended ~~June~~September 30, 2020 and consisted primarily of the purchase of property and equipment in connection with the Company occupying its corporate headquarters during the first quarter of 2019.

Net cash provided by financing activities

Net cash provided by financing activities was $44.6 million for the ~~six~~nine months ended ~~June~~September 30, 2020 and consisted primarily of net proceeds of $35.4 million from an underwritten public offering of common stock for 15,180,000 shares of common stock of the Company. The Company also received net proceeds of $5.1 million from a registered direct offering with certain institutional investors, which included Armistice, that closed in February 2020 for the sale of 1,306,282 shares of common stock of the Company and net proceeds of $3.9 million from a private placement of equity securities with Armistice during March 2020.

Net cash provided by financing activities was ~~$8.9~~$12.4 million for the ~~six~~nine months ended ~~June~~September 30, 2019 and consisted primarily of net proceeds of approximately $9.0 million from the underwritten public offering of common stock for 1,818,182 shares of common stock of the Company. The Company also received net proceeds of $3.7 million from a private placement of equity securities with Armistice during the third quarter of 2019. Additionally, for the ~~six~~nine months ended ~~June~~September 30, 2019, the Company received net proceeds of $0.3 million of proceeds from exercise of stock options and warrants and $0.1 million of proceeds from sales of common stock under the employee stock purchase plan. The increase was partially offset by ~~$0.4~~$0.6 million payment of contingent consideration related to the Avadel pediatric product's acquisition.

Critical Accounting Policies, Estimates, and Assumptions

This Management’s Discussion and Analysis of Financial Condition and Results of Operations is based on our unaudited condensed consolidated financial statements included in this Quarterly Report, which have been prepared in accordance with GAAP. In preparing the financial statements in conformity with GAAP, the Company makes estimates and assumptions that have an impact on assets, liabilities, revenue and expenses reported. These estimates can also affect supplemental information disclosed by us, including information about contingencies, risk, and financial condition. In our unaudited condensed consolidated financial statements, estimates are used for, but not limited to, revenue recognition, cost of product sales, stock-based compensation, fair value measurements (including those relating to the Guarantee and Investment in Aytu), cash flows used in management's going concern assessment, income taxes, goodwill, and other intangible assets and clinical trial accruals. The Company believes, given current facts and circumstances, that our estimates and assumptions are reasonable, adhere to GAAP and are consistently applied. Inherent in the nature of an estimate or assumption is the fact that actual results may differ from estimates, and estimates may vary as new facts and circumstances arise. Our most critical accounting estimates and assumptions are included in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 11, 2020 except for the recently adopted accounting standards described in Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this

~~Table of Contents~~

Quarterly Report on Form 10-Q. There have been no material changes to our critical accounting policies during the ~~six~~nine months ended ~~June~~September 30, 2020

Table of Contents

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as defined by applicable SEC rules and regulations.

Recently Adopted Accounting Pronouncements

See Item 1 of Part I, “Notes to Unaudited Financial Statements,” Note 2, of this Quarterly Report on Form 10-Q.

JOBS Act

The JOBS Act contains provisions that, among other things, reduce reporting requirements for an “emerging growth company.” As an emerging growth company, we have elected to not take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies.

4441

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Risk

As a smaller reporting company, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) and Rule 15d-15(b) of the Exchange Act, our management, including our principal executive officer and our principal financial officer, conducted an evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q of the effectiveness of the design and operation of our disclosure controls and procedures. In designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of the end of the period covered by this Quarterly Report on Form 10-Q.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

4542

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

In November 2017, Cerecor acquired TRx Pharmaceuticals, LLC ("TRx") and its wholly-owned subsidiaries, including Zylera Pharmaceuticals, LLC, and its franchise of commercial medications (the "TRx Acquisition"). TRx was owned by Fremantle LLC ("Fremantle") and LRS International, LLC ("LRS", and collectively, the "former TRx owners"). ~~A portion~~Various disputes and claims arose between Cerecor, including a member of ~~the consideration for TRx Acquisition included shares~~Cerecor's board of ~~Cerecor common stock. The TRx Acquisition also included certain earn-outs for~~directors (the "Cerecor Parties"), and the former TRx owners, ~~for Cerecor achieving gross profit targets in~~which ultimately led to the ~~sales~~parties entering into a settlement agreement on August 28, 2020. As part of the ~~TRx acquired products. Currently,~~settlement agreement, Cerecor made a $0.9 million payment to the former TRx owners ~~beneficially own more than 10%~~to settle all known disputes and claims between all parties. Additionally, the settlement agreement released all parties from other disputes and claims whether matured or unmatured and/or whether known or unknown from the beginning of ~~Cerecor's outstanding common stock.~~

~~On December 19, 2019, Cerecor,~~time through ~~its law firm, received a letter from an attorney on behalf of~~ the former TRx owners dated December 18, 2019, which enclosed a draft complaint seeking relief against Cerecor and one of the members of its board of directors. The letter further threatened that if an immediate discussion regarding a settlement ~~did not occur, that the lawsuit would be filed on December 24, 2019. The parties met for a pre-lawsuit mediation in June 2020, however no resolution was reached. As of the~~ date of ~~this filing, no lawsuit has been filed.~~August 28, 2020. The ~~proposed complaint indicates that~~Company recognized the ~~former TRx owners would seek~~$0.9 million charge within general and administrative expenses for the following relief: (a) $3,000,000 on the grounds that commercially reasonable efforts to sell the acquired TRx products would have resulted in the gross profit earn-out target being reached; (b) that the $3,000,000 amount be trebled as a result of Cerecor's alleged improper conduct; (c) $9,200,000 as a result of alleged losses resulting from the alleged improper treatment of the former TRx owners as affiliates;three and (d) the removal of any restrictions on the former TRx owners' shares of common stock in Cerecor. Cerecor disputes that the former TRx owners are entitled to the relief sought and intends to vigorously defend against any lawsuit filed on behalf of the former TRx owners.nine months ended September 30, 2020.

Item 1A. Risk Factors.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 11, 2020, , our Quarterly Report on Form 10-Q filed with the SEC on May 7, 2020 and our Current Report on Form 8-K filed with the SEC on June 9, 2020 which could materially affect our business, financial condition, or future results. Our risk factors as of the date of this Quarterly Report on Form 10-Q have not changed materially from those described in the Form 10-K, 10-Q and 8-K referenced above. The risks described in the Form 10-K, 10-Q and 8-K referenced above are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, or future results of operations and the trading price of our common stock.

4643

Table of Contents

Item 6. Exhibits.


Exhibit Number						Description of Exhibit

~~10.25#~~						Employment Agreement, dated September 26, 2019, by and between Cerecor Inc. and Christopher Sullivan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on April 27, 2020).

~~10.26#~~						~~Letter Agreement, dated April 23, 2020, by and between Cerecor Inc. and Christopher Sullivan (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on April 27, 2020).~~

~~10.27#~~						~~Separation Agreement, dated April 24, 2020, by and between Cerecor Inc. and Simon Pedder (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed on April 27, 2020).~~

~~10.28*+~~						~~Amended and Restated Clinical Development and Option Agreement, dated May 28, 2020, by and between Aevi Genomic Medicine, LLC and Kyowa Kirin Co., Ltd., formerly known as Kyowa Hakko Kirin Co., Ltd.~~

~~10.29#~~						~~Cerecor Inc. Third amended~~ ~~and~~ ~~Restated~~ ~~201~~6 ~~Equity Incentive Plan (incorporated by~~ ~~reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 18, 2020).~~

31.1+						Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2+						Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1+†						Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of ~~2002~~.2002.

101						Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Condensed Consolidated Balance Sheets as of ~~June~~September 30, 2020 and December 31, 2019; (ii) Condensed Consolidated Statements of Operations (Unaudited) for the Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2020 and 2019; (iii) Condensed Consolidated Statements of Cash Flows (Unaudited) for the ~~Six~~Nine Months Ended ~~June~~September 30, 2020 and 2019; (iv) Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) for the Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2020 and 2019; and (v) Notes to Unaudited Financial ~~Statements~~Statements.

104						Cover Page Interactive Data File, formatted in iXBRL (included in Exhibit ~~101~~101).

~~# Management contract or compensatory agreement.~~

* Portions of this exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K.

+ Filed herewith.

† This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

4744

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Cerecor Inc.

Date: ~~August 6,~~November 9, 2020

/s/ Christopher Sullivan

Christopher Sullivan

Interim Chief Financial Officer

(on behalf of the registrant and as the registrant’s principal financial officer and principal accounting officer)

4845


	Warrant		Unit purchase		Contingent
	liability		option liability		consideration		Total
Balance at December 31, 2019	$	3,460	$	10,594	$	—	$	14,054
Change in fair value	(3,440)		(10,488)		—		(13,928)
Balance at June 30, 2020	$	20	$	106	$	—	$	126